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Abstract 
Characterizing the cellular participants in tissue immune responses is critical for 
understanding infection, cancer, autoimmunity, allergy, graft rejection, and other 
immunological processes. Leukocytes recirculate through blood vessels before 
localizing to tissue sites of immune responses. Thus, in experimental animal 
models, tissues are often perfused to putatively remove blood-borne leukocytes 
that may conflate analysis. Here, we develop and validate an intravascular 
staining methodology that distinguishes between vascular and tissue-localized 
cells of the immune system. We demonstrate that perfusion both fails to remove 
many blood-borne leukocytes and also may remove tissue-localized populations 
of interest, and we provide examples of how this issue distorts interpretation of 
leukocyte differentiation state, migration, and phenotype in healthy mice, as well 
as those responding to viral or Mycobacterium tuberculosis infection or tumor 
challenge. Additionally, we utilize intravascular staining to examine resident 
memory T cells in non-lymphoid tissues, such as the lung, liver and female 
reproductive tract. This study highlights the breadth and gravity of the issues 
regarding tissue leukocyte composition, outlines simple methods for identification 
of various intravascular leukocyte populations, reviews the limitations of the 
technology, and demonstrates that these methods should be routinely adopted in 
lieu of perfusion for interpretable and accurate analyses of immune responses in 
many tissues. 
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Respiratory Infections 
Lower respiratory tract infections (LRIs or LRTIs), involving the trachea, 
bronchial tubes, bronchioles and lungs, are the third leading cause of death in 
the world (behind only ischaemic heart disease and stroke), and they are the 
leading cause due to infectious disease (1). Bronchioles of the lower respiratory 
tract branch into alveoli, tiny air sacs separated from blood vessels by a cell layer 
only 2µm thick. This intimate barrier permits efficient gas exchange, a critical 
function of the lung, but it also allows for a major vulnerability: the only separation 
between environmental agents and the vascular circulation are a fused alveolar 
pneumocyte and a capillary endothelial cell with a shared basement membrane. 
During an infection of the lung, the immune system must maintain a delicate 
balance between effector functions, which attempt to prevent systemic disease 
by eliminating or containing the pathogen, and pathology, which may induce fatal 
damage to the host. 
 To reduce vulnerabilities to infection, the respiratory tract consists of 
numerous physical barriers, including tight junctions between epithelial cells and 
the mucociliary escalator. Mucous-secreting goblet cells (2), ciliated epithelium, 
and commensal bacteria comprising the lung microbiome (3) all contribute critical 
protective functions in the lower respiratory tract. Further, the innate arm of the 
immune system, consisting of polymorphonuclear cells (PMNs or neutrophils), 
mononuclear phagocytes (monocytes, macrophages, and dendritic cells), and 
innate lymphoid cells mount an immediate response to foreign material, which is 
often sufficient to prevent the spread of infection. However, despite these diverse 
3 
defense mechanisms, some pathogens escape elimination. In these cases, 
antigen-specific T- and B-lymphocytes of the adaptive immune response are 
often required for pathogen control and clearance. 
 
Immune responses to viral infection 
During an infection, cells of the innate and adaptive immune system work 
in concert to contain and clear the infectious agent. Upon initial exposure to virus, 
cells of the innate immune system recognize foreign viral material by detecting 
pathogen associated molecular patterns (PAMPs) through pattern recognition 
receptors (PRRs). PAMPs can be in the form of nucleic acids (DNA or RNA), 
proteins, or cellular damage caused by infection. Pathogen recognition results in 
the recruitment of additional inflammatory cells to the site of infection and 
activation of naïve lymphocytes in lymphoid tissue.  
An immune response against infectious virus is initiated when an aspect of 
the virus is detected either by infected host cells or by neighboring cells of the 
innate immune system. The three major classes of phagocytic cells, 
macrophages/monocytes, granulocytes, and dendritic cells, detect pathogens 
using PRRs. Viral nucleic acid sensing can occur in the cytoplasm through RIG-I-
like receptors (RLRs) and melanoma differentiation-associated 5 (MDA-5), which 
detect viral RNA (4-7), or AIM2-like receptors (ALRs), which detect viral DNA (8-
15). Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) (8, 
10, 12, 14-16), such as NLRP3, detect cell stress or damage in the cytoplasm 
and initiate formation of the inflammasome complex. Detection of viral nucleic 
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acids can also occur in endosomes through toll-like receptors (TLRs), specifically 
TLR3 (16-18), TLR7 (17-20) and TLR9 (19-21). Detection of viral PAMPs triggers 
phagocytic cells to produce and secrete anti-microbial peptides, chemokines, and 
the anti-viral cytokines interferon (IFN)-α and IFN-β, which contribute to the 
induction and maintenance of inflammation as well as containment of the 
infection.   
Almost all cell types in the body are capable of producing IFN-α and IFN-
β, also referred to as type I IFNs, upon detection of viral RNA via the cytoplasmic 
PRRs RIG-I and MDA-5 (21-24). However, some cell types, such as the 
plasmacytoid subset of dendritic cells, are capable of producing abundant levels 
of type I IFN during viral infection (22-26). IFNs were named for their ability to 
interfere with viral replication in infected cells in vitro. In vivo, IFN signaling 
induces resistance to viral infection in nearby uninfected cells by activating genes 
that degrade cytoplasmic mRNA and inhibit translation. In addition, IFN signaling 
also increases major histocompatibility complex (MHC) expression and antigen 
presentation (25-28), activates dendritic cells, macrophages, and natural killer 
(NK) cells (27-32), and induces expression of chemoattractant molecules (29-
33). Collectively, IFN signaling limits viral replication, sustains inflammatory cues, 
and plays a role in the initiation of the adaptive immune response. 
The innate arm of the immune response utilizes numerous PRRs to detect 
a broad range of foreign material. Lymphocytes of the adaptive immune system, 
however, express receptors allowing for recognition of unique epitopes, a 
phenomenon referred to as antigen-specificity. During development, B and T 
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lymphocytes undergo unique gene rearrangements to express antigen-specific 
receptors on the cell surface with very specific binding capabilities. B cells 
express a B cell receptor (BCR) with direct antigen-binding abilities; 
consequently, BCRs recognize both the peptide sequence and spatial 
conformation of antigens. T cells, however, express T cell receptors (TCR) that 
bind to peptide in MHC expressed on the surface of antigen-presenting cells 
(APC). The TCRs of CD8 T cells bind to peptide in MHC class I (MHC I) 
molecules, while the TCRs of CD4 T cells bind to peptide in the context of MHC 
class II (MHC II). CD8 and CD4 T cells are also identified by their expression of 
the co-receptors CD8 and CD4, respectively, which stabilize TCR interactions 
with the peptide:MHC complex.  
Activation of naïve T cells requires three distinct signals from professional 
APCs (34, 35) (of note: while macrophages and B cells have the ability to present 
antigen to T cells in the context of MHC II, professional APCs involved in T cell 
activation are usually dendritic cells (33, 36, 37)). PRR ligation and IFN signaling 
at the site of infection result in dendritic cell maturation and migration to 
lymphatic tissue and subsequent lymphocyte activation. In this way, dendritic 
cells form a critical link between the innate and adaptive arms of the immune 
response.  
The first APC:T cell signal consists of a peptide:MHC and TCR interaction 
(34, 38). The second involves the interaction of co-stimulatory molecules B7.1 
(CD80) or B7.2 (CD86) on the APC and CD28 on the T cell (36, 37, 39, 40). The 
third signal comes in the form of cytokines secreted by the APC (35, 38, 41-45). 
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This combination of activating signals initiates clonal expansion and 
differentiation of the activated cells, resulting in an expanded population of T cells 
with the same antigen specificity. After priming, antigen-specific lymphocytes, 
which are rare in the naïve repertoire (approximately 20-200 naïve cells of each 
epitope specificity) (39, 40, 46), expand 100- to 50,000-fold (35, 41-48), resulting 
in an abundant population in secondary lymphoid tissue (Figure 1-1). Importantly, 
if any of the three signals is absent during activation, T cells are programmed to 
follow an unresponsive fate (46, 49). T cells receiving incomplete activation 
signals often undergo clonal deletion, anergy induction, tolerization, or 
differentiation into regulatory cells (46-48, 50). 
The signal three cytokines from APCs also initiate a differentiation 
program in activated cells, allowing for acquisition of effector functions. Once 
activated, effector cells no longer require co-stimulation to exert their functions. 
Activated B cells begin to secrete BCR in the form of antibody. Activated CD8 T 
cells adopt cytotoxic effector functions, such as Granzyme B and IFN-γ 
production, for defense against intracellular pathogens. CD4 T cells differentiate 
down effector lineage pathways based on which cytokines were secreted by 
APCs during activation (38, 51). To date, numerous CD4 T cells subsets have 
been characterized on the basis of transcription factor expression and cytokine 
secretion (49, 52). For example, naïve T cells differentiate into TH1 cells when 
activated in the presence of IFN-γ and interleukin (IL)-12 (50, 53, 54). TH1 cells 
provide protection against intracellular pathogens, such as viruses and 
intracellular bacteria, and are defined by the expression of the transcription factor 
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T-bet and secretion of IL-2 and IFN-γ (38, 55-57). Upon activation, T cells also 
begin to express receptors that direct egress from the spleen and lymph nodes 
and promote migration to non-lymphoid tissues (52, 58). 
  
Figure 1-1: T cell expansion, contraction and maintenance after antigen 
stimulation. The naïve repertoire contains a vast number of T cells that express 
unique T cell receptors. Prior to antigen exposure, the frequency of these cells in 
the circulation is very rare. Upon exposure to antigen and activating signals, 
antigen-specific T cells proliferate and differentiate. After clearance of the 
antigen, the expanded population contracts, yielding a relatively stable memory 
pool. These memory cells are capable of rapid expansion and effector function 
upon repeated exposure to antigen. 
 
In contrast to T cells, which require interactions with mature DCs for 
priming, B cells undergo activation through interactions with antigen and 
activated CD4 T cells (53, 54, 59-61). BCR ligation induces both intracellular 
signaling and antigen internalization. Antigen is subsequently processed and 
presented on MHC II molecules to CD4 T cells. Helper T cells previously primed 
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by mature DCs express co-receptors, such as CD40 ligand (CD40L) and 
inducible costimulator (ICOS) (55-57, 62, 63), and secrete cytokines, such as IL-
4, IL-5, IL-6, and B cell activating factor of the tumor necrosis factor family 
(BAFF), that induce proliferation and differentiation of B cells expressing cognate 
peptide:MHC II (58, 64). In the secondary phase of B cell activation, activated B 
cells migrate into follicles within the secondary lymphoid organ, continue 
proliferation, and form germinal centers (59-61, 65). Further interactions with 
CD4 T cells of the follicular helper lineage (TFH) in the germinal center initiate 
somatic hypermutation (62, 63, 66), affinity maturation, and class switching (64, 
67-69). Activated B cells differentiate into either antibody-secreting cells 
(secreting a soluble form of the BCR; also known as plasma cells) or memory 
cells (65, 70, 71) (which do not secrete soluble BCR). This process yields long-
lived B cell memory as well as the production of both high affinity antibodies and 
antibodies of different isotypes with distinct effector functions (66, 72). 
Effector B and T cells make fundamentally different contributions to the 
overall immune response. For instance, antibodies contribute to neutralization or 
opsonization of infectious agents and toxins (67-69, 73, 74). T cells, on the other 
hand, do not produce soluble TCR. Instead, T cells participate in myriad diverse 
protective effects within the host. CD8 T cells secrete cytokines and exhibit 
contact-dependent cytotoxicity during infection, killing infected cells in a 
controlled manner to prevent pathogen spread (70, 71, 75). CD4 T cells influence 
the behavior of other cells by exhibiting cytotoxicity (76, 77), activating 
macrophages (TH1) (72, 78, 79), recruiting and activating eosinophils, mast cells 
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and basophils (TH2) (73, 74, 80), promoting inflammation (TH17) (35, 42, 75), 
providing help to B cells during activation (T follicular helper (TFH)) (35, 42, 45, 
76), or suppressing other lymphocytes (T regulatory cells (Tregs)) (78, 79, 81). 
This combination of approaches to preventing pathogen dissemination 
throughout the body is sufficient to clear the infectious agent in the vast majority 
of cases. In the event that the innate and adaptive arms of the immune response 
are unable to clear a pathogen, chronic infection is established within the host; 
the regulatory capacity of T cells serves to reduce immune-mediated damage 
within host tissue and establish a new homeostatic equilibrium between host-
pathogen interactions (80-82).  
 In acute infections, proliferating lymphocytes reach a peak in population 
size that correlates with control of the pathogen (Figure 1-1). Upon control or 
clearance of an infectious agent, the population of effector cells undergoes 
contraction (35, 42, 83). Approximately 90-95% of the antigen-specific population 
undergoes coordinated and controlled cell death, also known as apoptosis (35, 
42, 45, 84-86). Lymphocytes that remain after contraction form a long-lived 
memory population, which is maintained in both lymphoid and non-lymphoid 
tissues, poised to mount a rapid response against future infections.  
  
Lymphocyte migration  
Leukocyte migration is a coordinated process involving alterations in 
expression of a variety of molecules and on a variety of cell types. Despite the 
great diversity in these molecules at the molecular level, the multistep paradigm 
10 
of cellular migration from blood into tissue is remarkably conserved. The central 
dogma regarding leukocyte migration involves several major steps: rolling, 
integrin activation, arrest, and transmigration (Figure 1-2). Blood circulating 
through the body reduces velocity upon entry of post-capillary venules (81, 87), 
which are wider in diameter than capillaries. Hemodynamic forces, such as shear 
forces near the edges of endothelial vessels, and interactions with red blood cells 
(RBC) (81, 82, 88) also contribute to the reduced velocity of leukocytes traveling 
in the blood. Interactions between selectins and carbohydrate molecules allow 
leukocytes to adopt a “rolling” motion along the endothelial surface. This motion 
allows for ligation of chemokine receptors on leukocytes with chemokines 
expressed on the vascular endothelium; G-protein coupled intracellular signaling 
subsequently activates integrins on leukocytes (83, 89). Integrin activation and 
firm adhesion to the endothelial surface results in cell arrest. Once leukocytes 
have stopped moving laterally, transmigration (also referred to as extravasation, 
the process of leukocytes squeezing between endothelial cells, or diapedesis, 
the process of leukocytes passing through the basement membrane) through the 
vascular endothelium into the tissue occurs (90-93).  
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Figure 1-2: T cell migration three-step paradigm. Leukocytes engage in a 
coordinated process to traffic from blood into tissue. Selectin ligation allows cells 
to “roll” along the endothelium, chemokine receptor ligation activates integrins on 
the leukocyte surface, and integrin interactions with addressins on the endothelial 
surface results in firm adhesion. Upon arrest, cells extravasate into the tissue. 
 
While the specific selectins, chemokine receptors and integrins involved in 
trafficking from the vasculature into organs of the body vary, the general multi-
step migratory process is conserved in lymphoid and non-lymphoid tissues, both 
under inflamed and steady state (uninflamed) conditions (94, 95). For instance, 
L-selectin (CD62L) is expressed on naïve lymphocytes and interacts with the 
carbohydrate moiety sulfated sialyl-Lewisx on high endothelial venules (HEV) in 
lymph nodes, which initiates rolling (96, 97). Chemokine receptor 7 (CCR7) on 
naïve lymphocytes binds to chemokine ligands 19 and 21 (CCL19 and CCL21, 
respectively), presented on the vascular surface of high endothelial venules in 
lymph nodes (84-86, 98, 99). Downstream signaling results in the activation of 
the leukocyte integrin LFA-1 (composed of the αL:β2 heterodimer, also known as 
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CD11a:CD18). Interactions between LFA-1 on lymphocytes and ICAM adhesion 
molecules (ICAM-1 and ICAM-2) on the blood vessel wall result in firm adhesion 
and arrest. [It should be noted that there are some exceptions to this migratory 
paradigm. For example, in the absence of CD62L, the integrin α4:β7, which is 
expressed at low levels on naïve T cells, can interact with mucosal vascular 
addressin cell adhesion molecule 1 (MADCAM-1), and is sufficient to initiate 
rolling and entry of naïve lymphocytes into gut-associated lymphoid organs, such 
as Peyer’s patches and mesenteric lymph nodes (87, 100).] This selective 
trafficking of naïve lymphocytes to lymphoid tissues increases the likelihood that 
rare, naive antigen-specific cells will encounter mature APCs and become 
activated during an immune response.       
 During a viral infection in the respiratory tract, a subset of activated DCs 
capable of presenting viral antigens traffics to the draining mediastinal lymph 
nodes. Five distinct populations of lung DCs have been described in mice to date 
using a combination of phenotype and location within the lung. Resident cDCs 
(CD11c+ CD11b+ Langerin+ CD103+), plasmacytoid DCs (pDC; CD11cdim, 
CD11b-, Siglec H+), and alveolar DCs (CD11c+ CD11b+/-) are found in the lung 
under non-inflammatory conditions. Under inflammatory conditions, inflammatory 
monocyte-derived DCs (CD11c+ CD11b+ Ly6c+ SIRP-1α) and interferon-
producing killer DCs (iKDC; CD11cdim CD11b- B220+ CD19- NK1.1+) are also 
present (101, 102). Each subset is thought to play a distinct role in T cell 
activation. For instance, CD103+ cDCs have been shown to be essential for 
priming of CD8 T cells in the draining lymph node after influenza infection (103, 
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104), while CD11c+ CD11b+ DCs are critical for inducible bronchus associated 
lymphoid tissue (iBALT) generation and maintenance (82, 88).   
Once activated DCs reach the draining lymph node, naïve T and B cells 
become activated, proliferate, differentiate, and begin to express chemokine 
receptors and integrins that facilitate migration back to the lung.  To date, CCR5 
(89, 105, 106), CXCR6 (90, 92, 93, 107), and CXCR3 (94, 108-110) have been 
shown to be important for T cell migration to the respiratory tract. However, 
CCR5 and CXCR3 have been demonstrated to be important receptors for 
migration to a variety of non-lymphoid tissues, such as skin and small intestine 
(96, 108, 109, 111). The collagen-binding integrin α1β1 (VLA-1, the α1 component 
is also known as CD49a) (98, 99, 112, 113), as well as the interaction between 
lymphocyte function-associated antigen-1 (LFA-1) and very late antigen-4 (VLA-
4) (100, 114), have also been implicated as mediators of lung-specific T 
lymphocyte migration. Whether these or other as of yet unidentified receptors are 
responsible for lung-specific homing remains to be determined.  
Importantly, studies tracking the circulation of neutrophils through the lung 
vasculature have demonstrated a substantial difference in transit time depending 
on the route of cell passage. Neutrophils traveling through large blood vessels 
transit through the lung in roughly 3 minutes, while neutrophils migrating through 
the capillary beds require closer to 3 hours to completely transit the lung (101, 
115-117). Consequently, neutrophils are enriched ~100 fold within the lung 
capillaries over the large lung vessels. In other words, even though capillaries 
only contain ~40% of the blood volume within the lung, they consist of ~99% of 
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the blood-borne neutrophils. Erythrocytes, which are of a similar diameter to 
leukocytes (103, 118), must also transit these narrow capillary segments. 
However, unlike leukocytes, erythrocytes are capable of deforming (82, 119-
126), allowing transit through the lung vasculature without restriction. These 
results with respect to restricted neutrophil migration through pulmonary 
capillaries support the hypothesis that lymphocytes may also be sequestered 
within lung vasculature.   
While the paradigm of lymphocyte migration necessitates roles for 
selectins, chemokines, and integrins, some data suggests that these 
requirements are dispensable for leukocyte migration to the lung tissue. A role for 
selectins has been described in lymphocyte migration to the lung (105, 106, 127), 
while others suggest that selectins are not critical for trafficking to this tissue 
(107, 128-133). Although chemokine ligation and integrin activation are thought 
to be major initiating factors of diapedesis, several reports have indicated this 
process may be dispensable for lymphocyte migration to the lung (108-110, 134-
136). Furthermore, some reports indicate that naïve lymphocytes, which lack 
expression of the chemokine receptors suggested to be critical for lung homing, 
are capable of migrating to uninflamed lung tissue (108, 109, 111, 122, 137-141).  
In addition to reports suggesting that the requirements for naïve B and T 
cell migration to the lung tissue are unique, some reports also suggest that cells 
of the myeloid lineage have unique migratory properties with respect to the lung. 
For instance, upon extravasation from the circulation, tissue-specific factors 
induce monocytes to differentiate into macrophages or monocyte-derived DCs 
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(142-146). However, it has also been suggested that monocytes can circulate 
through the lung tissue without differentiating (147-149). These conflicting 
interpretations of leukocyte homing requirements and differentiation states within 
the lung tissue necessitate a re-evaluation of this phenomenon. A clear 
understanding of the mechanism of lymphocyte migration is critical for 
determining the factors that are important for mounting an effective protective 
response against infection.  
 
Memory T cell heterogeneity 
Upon clearance of a viral infection, expanded primary effector 
lymphocytes undergoes contraction, resulting in a memory population of antigen-
specific cells (Figure 1-1). While this population contains only a fraction of the 
number of cells that were present during the effector stage (~5-10%), the 
memory population persists with approximately 100-1000 fold greater frequency 
than what was initially present in the naïve repertoire (112, 113, 150, 151) and 
remains quite diverse in phenotype and functional capacity (114, 144, 152).  
 Immunological memory is long lived (115-117, 138, 153), and memory 
cells contribute to rapid protection against subsequent infection. Rapid protection 
can be attributed to several important differences between naïve and memory T 
cells: differentiation state, frequency, and proximity to the site of antigen 
encounter. Like effector T cells, memory T cells are poised to exert effector 
functions immediately upon TCR recognition of the appropriate peptide:MHC 
complex without secondary activation signals by APCs. Additionally, the 
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increased frequency of antigen-specific memory cells in the repertoire (compared 
to naive cells) increases the chances of antigen encounter. Finally, memory cells 
are positioned within non-lymphoid tissues, particularly at barrier surfaces, such 
as the respiratory, digestive, and urogenital tracts, where epithelial breach and 
infection can occur. This positioning allows memory cells an opportunity to detect 
and clear an infectious agent before the infection spreads systemically. Thus, 
there is great interest in understanding the development and maintenance of 
immunological memory in mucosal tissues, especially for immune-evasive agents 
such as human immunodeficiency virus (HIV), herpes simplex virus (HSV), 
Mycobacterium tuberculosis (Mtb), and influenza virus. 
 The T cell memory population was originally defined by expression of the 
lymphoid homing molecules CD62L and CCR7 (118, 138, 153, 154). T cells 
expressing these molecules are termed central memory T cells (TCM), which 
retain the ability to circulate through secondary lymphoid organs, blood and 
lymph. T cells lacking these molecules are termed effector memory T cells (TEM) 
and may be found circulating throughout the body. Consequently, TEM can be 
found predominantly in non-lymphoid tissues, blood and lymph. A subset of 
memory T cells that lack expression of CD62L and CCR7 (hence, cells that were 
originally classified as TEM) are now known to reside within tissues without egress 
to the circulation. These cells are known as resident memory T cells (TRM), and 
they have been identified in many non-lymphoid tissues, including small intestine 
epithelium, skin, female reproductive tract, brain, kidney, and lung (119-126, 
155), as well as some secondary lymphoid organs (156). However, within the 
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memory T cell compartment, “TCM” and “TEM”, as well as “TRM”, are very broad 
means of characterizing an extremely diverse population of cells.    
Originally, proliferative potential and effector function, in addition to 
recirculation migration patterns, were used as the primary parameters for 
distinguishing subsets of memory T cells (126, 127). For example, TCM have 
been shown to have superior proliferative potential and greater longevity than 
cells within the TEM category, whereas TEM generally maintain heightened effector 
capacities (155, 157-159). However, increasing evidence suggests that 
heterogeneity exists beyond these classifications as well. Many cell-extrinsic 
conditions, such as the cytokine milieu under which T cells first encountered 
antigen, the duration and intensity of antigen exposure (128-133, 160), cues 
unique to the lymphoid site of priming (119, 134-136, 161), and unique non-
lymphoid tissue microenvironment factors (121-123, 137-141, 155), as well as 
cell intrinsic characteristics, such as transcription factor expression level (41, 42, 
142, 144-146), cellular metabolism (42, 147, 149, 162), cytolytic capacity (113, 
118, 150, 151), cytokine secretion profile, cytokine responsiveness (118, 144, 
152, 163, 164), and turnover rate, all contribute to diversity within the memory T 
cell population.  
By definition, the TRM subset of the memory T cell population remains 
within tissues rather than recirculating through the resting host. Studies in the 
small intestine epithelium and the epidermis of the skin have revealed novel 
characteristics of TRM populations. Intraepithelial lymphocytes (IEL) of the small 
intestine reduce expression of the receptors for IL-7 and IL-15, as well as the co-
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stimulatory molecule CD27 (123, 138, 153). IELs also retain cytolytic function 
and high Granzyme B expression, along with expression of the cell surface 
molecules CD69 and αEβ7 (the αE integrin is also referred to as CD103) (138, 
153, 154, 165, 166). While expression of CD69 is often correlated with recent 
antigen experience, IELs express CD69 even under germ-free conditions (155, 
162, 167), suggesting that expression of CD69 is not restricted to cells that have 
recently encountered antigen. In fact, CD69 expression is inversely correlated 
with expression of the sphingosine-1 phosphate receptor 1 (S1PR1), which in 
involved in sphingosine-1 phosphate (S1P) mediated egress from tissues (126, 
168, 169). Thus, CD69 is often used as a surrogate marker of TRM. In contrast to 
CD69, CD103 expression is regulated by tumor growth factor beta (TGF-β), 
which is expressed constitutively within the small intestine epithelium (155, 158, 
159, 169, 170). The integrin CD103 binds to E-cadherin, which is expressed on 
epithelial cells (123, 160), and is thought to contribute to maintenance of IELs 
within the epithelium. While TRM isolated from the small intestine epithelium and 
epidermis of the skin almost unanimously express high levels of CD69 and 
CD103 (113, 119, 161), TRM within other non-lymphoid tissues, such as the 
salivary gland and female reproductive tract (119, 121, 123, 155) do not, which 
suggests that not all TRM express these molecules. Thus, the fidelity of these cell 
surface molecules as bona fide markers of residency remain to be determined. 
Memory T cells can exert cytotoxic function in both antigen-specific (41, 
42, 171-175) and bystander manners (42, 162, 176) to provide protection. 
Memory T cells that encounter antigen contribute to secondary immune 
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responses through rapid proliferation (113, 118, 176), immediate cytotoxic 
effector mechanisms (118, 163, 164, 176), and recruitment of additional immune 
effectors to the site (123, 174). Importantly, bystander activation via cytokine 
signaling (165, 166, 176) or NKGD2 ligation on antigen-nonspecific T cells 
results in CD8 T cell cytotoxicity (162, 167, 177) and, in some model systems, 
protective immunity (162, 178).  
 During anamnestic responses to respiratory infections, memory T cells are 
recruited to the lung tissue in an antigen-independent manner (179-182). IFN-α 
signaling promotes Granzyme B expression by recently recruited memory CD8 T 
cells within the lungs, which contributes to rapid cytotoxicity and control of viral 
replication (170, 183, 184). During influenza infections, heterosubtypic immunity 
provides significant protection against cross-reactive viral serotypes (168, 169, 
185, 186). Current studies investigating the kinetics of anamnestic responses 
against respiratory infections suggest that recruitment of memory T cells does 
not occur until more than 72 hours after infection (169, 170, 187). However, 
reports in other model systems have suggested memory T cell recruitment after 
viral infection can occur within 48 hours (123, 188-190). These kinetic variances 
may be due to differences in the route of infection or pathogenic agent used 
during secondary challenge; however, confounding factors, such as the lack of a 
distinction between vascular and tissue-localized cells in the lung, may also 
account for these discrepancies. Additional studies involving a more rigorous 
examination of memory T cell location within the lung are needed. 
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TCM have also been suggested to play an important role against 
secondary infections within the lung. For example, Wherry and colleagues 
performed adoptive transfer of equivalent numbers of sorted TCM and TEM 
populations, and demonstrated that TCM appeared to have greater protective 
capacity than TEM in the lung after intranasal infection (113, 188, 191-195). 
However, the experimental conditions employed greatly impact the interpretation 
of these data. For instance, protection was determined by viral titer five days 
after intranasal challenge; presumably, within this time frame APCs trafficked to 
secondary lymphoid tissues and reactivated TCM, inducing proliferation and 
differentiation into new effector T cells, which then likely trafficked to the lung and 
contributed to control of viral replication. The initial interpretation of the data was 
that TCM more effectively control viral replication. However, it is possible that the 
reduced protection afforded by TEM was due to the inability of the transferred 
memory cells to enter the lung tissue. The transferred memory cells were 
isolated from mice 45-60d after primary infection and injected into the vascular 
circulation of the recipient mice. It has been suggested that migration to some 
tissue compartments is restricted to cells in the effector differentiation state (119, 
196-199). Since the requirements for memory T cell migration to the lung tissue 
have not completely been defined, transferred TEM cells in this system may have 
been confined to the vasculature, resulting in a delayed protective response.  
To thoroughly investigate these incongruities, the employment of a 
technique distinguishing between T cells confined to the vascular and within the 
lung tissue is imperative. 
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Leukocyte responses to Mycobacterium tuberculosis 
T cells contribute significantly to protection against intracellular pathogens, 
but these infectious agents are not always viral in origin. For example, both CD4 
and CD8 T cells have been shown to make significant contributions to protection 
against the intracellular bacterium Mycobacterium tuberculosis (Mtb) (171-175, 
200, 201). The bacterium infects phagocytic alveolar macrophages and dendritic 
cells, which fail to fully eliminate the infection (176, 202). Activated T cells 
specific for Mtb traffic to the lung and secrete the cytokines IFN-γ and TNF-α, 
which activate infected macrophages to produce nitric oxide synthase (NOS), 
reactive nitrogen intermediates, and reactive oxygen species (ROS) (176, 203), 
limiting bacterial replication. However, even the presence of activated Mtb-
specific T cells within the lung often fails to completely clear the pathogen (176, 
204, 205); in fact, delayed T cell responses against Mtb have been reported 
(174, 205-207), and the chronic immunopathology induced by Mtb infection often 
results in an extended period of transmission to new hosts (176, 208-210). Thus, 
a thorough understanding of the contributions of lymphocytes to the Mtb immune 
response is essential for the development of effective preventative vaccines and 
immune-based treatments. 
Numerous subsets of myeloid cells are also involved in defense against 
Mtb. Neutrophils (Ly6G+, CD11b+ CD68-), inflammatory 
monocytes/macrophages (CD68+ Ly6C+, CD11b+, CD11c-), cDCs (CD68+, 
CD11b+/-, CD11c+), tissue-resident CD103+ cDCs (CD68+, CD103+, CD11b-, 
CD11c+), and inflammatory monocyte-derived DCs (moDC, CD68+, Ly6C+, 
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CD11b+, CD11c+) can all be isolated from the lungs of mice during Mtb infection 
(177, 211-216). However, the contributions of each subset to the overall immune 
response against Mtb are occasionally confounded by the presence of cells in 
the vasculature that are refractory to perfusion. The ability to distinguish cells in 
the lung vasculature from those in the Mtb-infected lung may identify major 
players in the immune response to Mtb.  
 
Leukocyte responses to solid tumors 
The immune system also plays a dynamic role in the removal of 
malignantly transformed cells from the body. Many tumors are detectable by 
antigen-specific lymphocytes (antigenic) and capable of provoking an immune 
response in an immune-competent host (immunogenic). Transformed cells are 
often removed through cytotoxic immune-mediated mechanisms, but tumors 
have developed myriad evasion techniques to avoid detection and eradication 
(178, 217-220).  
Two categories of tumor escape have been identified: immune exclusion 
(or ignorance) and immunosuppression (179, 181, 182, 221). Many solid tumors 
contain fibroblast reticular networks, dense collagen matrices, and vascular 
endothelium that simultaneously support tumor growth and prevent entry of 
immune cells from the blood. Tumor-associated fibroblasts can express 
immunosuppressive molecules (183, 184, 222). Thick collagen networks act as a 
barrier to T cell interaction with tumor cells (185, 186, 221). Endothelial vessels 
associated with tumors express higher levels of endothelin B receptor, which 
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suppresses T cell adhesion, a critical step in lymphocyte migration to tumor (187, 
223-225). Evasion mechanisms preventing immune cell penetration of solid 
tumors result in immune ignorance of the tumor. 
However, tumors are vastly heterogeneous with respect to initiation, 
expression of tumor-antigen, and microenvironment. In depth analysis of tumor 
microenvironments has revealed that many solid tumors contain dense immune 
cell infiltrate; yet, even in these tumors, eradication mechanisms fail. These 
tumors contain innate and adaptive cells capable of recognizing tumor antigens, 
but in cases of metastatic melanoma, these tumor-infiltrating effector cells have 
been shown to be unresponsive (188-190, 226, 227) and even suppressive (122, 
188, 191-195, 228).  
 Regulatory T cells are known negative regulators of tumor 
immunosurveillance (120, 122, 155, 196-199, 228, 229). Tregs suppress other 
immune cells through cell-cell contact dependent mechanisms and secretion of 
soluble inhibitory factors. Interactions between inhibitory cell surface molecules 
on Tregs, such as lymphocyte activation gene 3 (LAG-3) (200, 201, 229, 230), 
cytotoxic T lymphocyte antigen 4 (CTLA-4) (202, 231), and Galectin-1 (110, 203), 
with ligands on DCs (MHC II; CD80 or CD86; and CD45, CD43 or CD7, 
respectively) have been shown to reduce effective priming of naïve T cells and 
inhibit T cell function. Tregs expressing membrane bound TGF-β (mTGF-β) 
suppress the functionality, responsiveness and proliferative ability of both effector 
T cells and NK cells (107-109, 111, 204, 205, 232). Additionally, soluble factors 
such as IL-10, TGF-b, prostaglandin E2, and immunosuppressive metabolites 
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have been shown to be important for suppression (205-207, 233). Tregs also 
secrete perforin and granzymes that initiate cytolysis in effector T cells, B cells, 
monocytes, DCs, and NK cells (113, 208-210).  In both human and mouse 
models of disease, Tregs have been identified within solid and hematological 
malignancies. In fact, the proportion of Treg to effector T cells has been used for 
assessing disease severity, tumor burden, and likelihood of treatment 
effectiveness (180, 211-216). Notably, depletion or blockade of Tregs in cancer 
models results in increased potency of effector cell function. While Treg plasticity 
remains controversial, Tregs have been shown to adopt CD4 effector T cell 
functions in the context of certain inflammatory signals (217-220, 234). 
Consequently, a more thorough analysis of Tregs and the tumor factors that 
control differentiation and plasticity is of critical importance for the development 
of more effective anti-tumor immunotherapies.  
In addition to T cells with suppressive functionality, cells of the innate 
lineage contribute to suppression of anti-tumor immune responses. Myeloid 
derived suppressor cells (MDSC) are a heterogeneous population of immature 
myeloid cells capable of suppressing immune responses (120, 122, 155, 179, 
221, 228). In mice, two subsets have been defined based on morphological 
differences: expression of Ly6C and Ly6G (113, 222, 235). MDSCs within the 
granulocytic subset are CD11b+ Ly6Clow Ly6G+ while monocytic MDSCs are 
CD11b+ Ly6Chigh Ly6G- (124, 221, 236, 237). Granulocytic MDSCs use ROS in a 
contact-dependent manner to suppress immune cell function, whereas monocytic 
MDSCs induce suppression via nitric oxide (NO) and arginase (155, 223-225). 
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Notably, MDSCs have also been shown to promote tumor development through 
non-immunological mechanisms of angiogenesis (238, 239) and metastasis (138, 
240).  
During chronic infection and cancer, the innate and adaptive immune 
responses cannot control replication and spread of the pathogen or transformed 
cells, respectively. A deeper understanding of the immune evasion mechanisms 
involved in these processes will aid in the discovery of therapeutic reagents. 
However, our current inability to precisely determine the location of cellular 
participants in these processes impedes our ability to refine our understanding of 
these nuanced scenarios. For example, tumor-specific cytotoxic CD8 T cells may 
be in the circulation but fail to extravasate into the tumor. In this case, CD8 T 
cells could be isolated from angiogenic tumors containing neovasculature, but 
the cells would not necessarily be in the appropriate location for optimal function. 
A method for elucidating the localization of cells within tissue or vasculature will 
further our understanding of immune evasion processes, such as tumor 
ignorance. 
 
Intravascular staining overview 
We hypothesized that current techniques could not distinguish leukocyte 
migration to, or differentiation within, the lung tissue from cells present within the 
lung vasculature. Therefore, we tested the idea that cells within the lung 
capillaries were refractory to removal by perfusion, and this cellular population 
confounded the tissue-localized cells during analysis. Intravascular injection of a 
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non-depleting antibody had previously been used to distinguish between 
lymphocytes in the blood and tissue (124, 155, 234, 241-243); however, these 
studies were each limited to the analysis of a single lymphocyte subset (e.g. CD8 
T cells, CD4 T cells, B cells) during immune responses to infection. As the 
reliability of this technique had never been confirmed, we aimed to both validate 
the use and define the limitations of intravascular staining. Moreover, we sought 
to advance this methodology such that any and all leukocyte subsets could be 
examined within the same experiment. Additionally, we examined the utility of 
intravascular staining in non-infectious models of disease. Thus, we adapted this 
technique for use in numerous lymphoid and non-lymphoid tissues and in 
multiple disease models. Consequently, we have been able to explore specific 
phenomena related to leukocyte differentiation, trafficking, and function in several 
murine models of disease.   
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Chapter 2 
 
Intravascular staining redefines lung CD8 T cell 
responses 
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Non-lymphoid T cell populations control local infections and also 
contribute to inflammatory diseases, thus driving efforts to understand the 
regulation of their migration, differentiation, and maintenance. Numerous 
observations indicate that T cell trafficking and differentiation within the lung is 
starkly different than what has been described in most non-lymphoid tissues, 
including intestine and skin. We found that >95% of memory CD8 T cells isolated 
from mouse lung via standard methods were actually confined to the pulmonary 
vasculature, despite perfusion. Respiratory route of challenge increased virus 
specific T cell localization within lung tissue, although only transiently. Removing 
blood-born cells from analysis by the simple technique of intravascular staining 
revealed distinct phenotypic signatures and chemokine-dependent trafficking that 
was restricted to antigen-experienced T cells. These results precipitate a revised 
model for pulmonary T cell trafficking and differentiation and a re-evaluation of 
studies examining the contributions of pulmonary T cells to protection and 
disease. 
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Introduction 
A dense network of pulmonary capillaries underlying the alveoli forms the 
structural basis of respiration. Gas exchange is most efficient at the thinnest 
portions of the air-blood barrier where narrow capillaries share a fused basal 
lamina with alveolar epithelium. This intimate association between the capillary 
bed, a thin permeable membrane, and the outside world, coupled with the fact 
that inflammation can disrupt the delicate architecture necessary for gas 
exchange, creates vulnerabilities. Indeed, lower respiratory infections account for 
the single greatest cause of death from infectious disease, and the incidence of 
chronic T cell dependent inflammatory diseases such as asthma are increasing 
(119, 226, 227). 
T cell differentiation is coupled with anatomic distribution. Naïve and 
central memory T cells (TCM) recirculate through secondary lymphoid organs, 
blood, and lymphatic vessels. This restricted homing pattern optimizes interaction 
with professional APCs and subsequent proliferation in response to cognate 
antigen recognition. Effector memory T cells (TEM) patrol non-lymphoid tissues 
where they are positioned for more immediate interception of pathogens at the 
most common points of exposure (155, 157). Indeed, resident TEM within skin 
contribute most rapidly to control of local re-infection (122, 136, 228, 244-247). 
Resident TEM populations have been defined in many non-lymphoid tissues, and 
are characterized by unique phenotypic signatures not represented in blood, 
including CD69 and CD103/β7 integrin (120, 122, 155, 228, 229, 247-253). 
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Regardless of route, infection or immunization give rise to extraordinarily 
large effector and memory T cell populations that can be isolated from perfused 
mouse lung (229, 230, 254). However, lung T cell migration and differentiation is 
less clear than in tissues such as the intestinal mucosa, skin, brain, or lymph 
nodes (LNs). In contrast to the stereotypic 3-step model of lymphocyte 
extravasation (231, 254), some evidence demonstrates that T cell homing to lung 
is chemokine-independent (110, 255-258). However, expression of chemokine 
receptors by T cells, including CCR5 and CXCR3, are required for normal 
distribution and differentiation of lung T cells following local infection (89, 101). In 
some infection models, the lung contains a large fraction of TCM (259-261). In 
fact, even naïve lymphocytes can be isolated from the perfused lung (107-109, 
111, 232). These observations contrast with most other non-lymphoid 
compartments, which do not contain TCM, exclude naïve T cells, and require 
chemokine signaling for entry. This study sheds light on these issues by refining 
our understanding of the anatomic compartmentalization of CD8 T cells within 
the lung. 
 
Results 
Pertussis toxin treatment of T cells yields increased recovery from lung  
We sought to confirm the pertussis toxin (PTx) sensitivity of memory CD8 
T cell homing to lung and other tissues, and also to address this issue for naïve 
CD8 T cells. Gp33-specific P14 memory CD8 T cells were generated in vivo in 
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response to i.p. lymphocytic choriomeningitis virus (LCMV) infection (referred to 
hereafter as P14 immune chimeras, see methods). Eight weeks later, 
splenocytes containing memory P14 CD8 T cells were treated with PTx or control 
media, then transferred i.v. into naïve recipients (Figure 2-1A). Three days after 
transfer, various tissues were harvested to assess T cell migration. Consistent 
with the known requirement for CCR7, migration to inguinal LN (ILN) was 
blocked by PTx treatment, and there was a reciprocal increase of donor cells 
among spleen and PBL. As reported previously, PTx treatment did not inhibit 
migration to lung, and like blood, actually led to an increase in recovered cells 
(Figure 2-1B). This experiment was repeated with naïve P14 CD8 T cells with 
similar results (Figure 2-1C). These data suggest that even naïve CD8 T cells 
home to lung in a chemokine independent process, particularly when LN homing 
was inhibited. 
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Figure 2-1: Pertussis toxin treatment of transferred T cells yields increased 
recovery from lung. (A) Naïve or memory P14 splenocytes were treated with 
pertussis toxin (PTx) or media control and transferred i.v. into naïve recipients. 
Tissues were harvested 1 (naïve) or 3 (memory) days after transfer. Frequency 
of memory (B) or naïve (C) P14 cells in PBL, spleen, ILN, or lung. Data are 
representative of 3 independent experiments totaling >12 mice/condition. Error 
bars indicate SEM. 
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In vivo staining distinguishes between anatomic compartments 
We wished to define which lung compartment naïve T cells migrated to. 
We injected anti-CD8α antibody (Ab) i.v. into naïve mice that had received 
untreated naïve P14 CD8 T cells. Three minutes later, blood was isolated, mice 
were immediately sacrificed and perfused with PBS, and tissues were quickly 
dissected, minced, and rinsed of free Ab. Lymphocytes were isolated via 
standard methods then stained with anti-CD8α surface Ab and other markers of 
interest. The permissiveness of donor naïve T cells to i.v. staining varied among 
distinct tissues (Figure 2-2): 100% of donor cells within blood, a subset of cells 
within spleen, and virtually no cells within LN were labeled. Like blood, 100% of 
naïve donor cells isolated from lung labeled with injected anti-CD8α Ab.  
 
Figure 2-2: Intravascular staining distinguishes between anatomic 
compartments. Naïve Thy1.1+ P14 splenocytes were transferred i.v. into 
C57Bl/6J mice. Anti-CD8α was injected i.v. Three minutes later, tissues were 
harvested. Cells were isolated and then stained ex vivo with anti-CD8β. Plots 
gated on Thy1.1+ lymphocytes. Data are representative of 3 independent 
experiments totaling ≥12 mice/condition. 
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PTx treatment increased the number of labeled donor cells recovered from blood, 
spleen and lung, but reduced the number of unlabeled cells recovered from 
spleen and ILN (Figure 2-3). 
 
Figure 2-3: PTx treatment prevents memory T cell entry to lymph nodes and 
white pulp of the spleen, resulting in more memory T cells in the blood and 
red pulp of the spleen. Memory P14 splenocytes were treated with PTx or 
media control and transferred i.v. into naïve recipients. Tissues were harvested 3 
days after transfer. Anti-CD8α was injected i.v. to distinguish between tissue 
compartments. Cells were isolated and then stained ex vivo with anti-CD8β. 
Number of i.v. Ab+ and i.v. Ab- naïve P14 cells, ± PTx treatment, isolated from 
tissues after transfer. Data are representative of 3 independent experiments 
totaling ≥12 mice/condition. 
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To assess whether intravascular staining was associated with distinct 
anatomic compartments, we injected anti-CD8α-PE Ab into P14 immune 
chimeras, sacrificed and perfused recipients, then immediately froze spleen and 
lung for immunofluorescence. Injected Ab labeled CD8 T cells in red pulp but not 
those in white pulp of spleen (Figure 2-4A). Lung tissue sections were also 
surface stained for CD8α-AF488, CD31-AF647 (which labels vascular 
endothelium), and DAPI (which labels cell nuclei). Analysis of the lung revealed 
that the vast majority of CD8 T cells were labeled only with injected Ab. Closer 
inspection revealed that these cells (red) appeared to be closely associated with 
pulmonary capillaries (blue, Figure 2-4B-E). These data indicate that most cells 
were exposed to injected Ab, and that in vivo staining blocked ex vivo surface 
staining on tissue sections. However, a small fraction of CD8α+ cells, typically 
surrounding airways and large blood vessels, were only labeled by ex vivo 
staining (green) of tissue sections, suggesting that they were protected from i.v. 
injected Ab (Figure 2-4 D&E). 
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Figure 2-4: In vivo staining distinguishes between anatomic compartments. 
(A) Spleen after anti-CD8α-PE i.v. injection. (B-E) Lungs of P14 immune 
chimeras were analyzed. CD8 T cells that stain with i.v. injected Ab (red) co-
localize with blood vessels (CD31, blue, see B and C), whereas those protected 
from i.v. Ab (green surface stain) are spatially distinct (D and E, ± DAPI, 
respectively). Arrows designate red i.v. Ab+ cells. Images are representative of 2 
independent experiments totaling 6 mice. Scale bars represent 100µm. 
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Migration to lung tissue is chemokine dependent 
Based on these data, it was possible that intravascular labeling of cells in 
the lung was restricted to cells contained within pulmonary capillaries or other 
blood vessels that were refractory to removal by perfusion. Alternatively, injected 
Ab may have leaked or been exported out of the pulmonary capillary bed, 
thereby staining perivascular cells. A collagen IV containing basement 
membrane underlies the lung vascular endothelium (as revealed by surface 
staining, Figure 2-5, lower left panel). We injected anti-collagen IV Ab and found 
that the basement membrane remained unlabeled, suggesting that the capillary 
bed did not allow rapid perivascular leakage of Abs (Figure. 2-5, lower right 
panel). For controls, we examined surface and injected collagen IV staining in the 
spleen (where only red pulp was exposed to injected Ab) and liver (which 
contains fenestrated endothelium within sinusoids, which permitted intravascular 
staining of basement membrane, Figure 2-5). 
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Figure 2-5: Intravascularly injected Ab does not label lung tissue under 
non-inflammatory conditions. Anti-collagen IV Ab (red) was injected i.v. prior to 
tissue harvest or tissue sections were surface stained ex vivo along with anti-
CD31 (yellow) and DAPI (gray). Images are representative of 2 independent 
experiments totaling 4 mice. Scale bars represent 100µm. 
 
To further test the interpretation that intravascular staining identifies cells 
contained within the capillary bed of the lungs of perfused mice, we revisited the 
issue of PTx insensitive lung trafficking. As in figure 1 A, PTx-treated or control 
memory CD8 T cells were transferred i.v. and recipient tissues were harvested 
three days later. The vast majority of untreated donor cells harvested from lung 
became labeled with injected Ab. However, a small fraction (~6%) was within a 
compartment of the lung that was protected from injected Ab. Importantly, 
appearance of this subset was PTx sensitive (Figure 2-6A&B), suggesting that it 
represented a chemokine dependent trafficking event. 
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Figure 2-6: Migration of memory CD8 T cells to uninflamed lung tissue is 
chemokine dependent. Thy1.1+ memory P14 splenocytes were treated with 
PTx or media and transferred i.v. into naïve C57Bl/6J mice. Intravascular anti-
CD8α staining and tissue harvest occurred 3 days later. (A) Representative flow 
cytometric analysis of the indicated recipient tissues. Plots gated on CD8b+ 
lymphocytes. (B) Number of donor memory P14 cells recovered from lung that 
were protected from intravascular staining (intravascular anti-CD8α negative). 
Plots are representative of 3 independent experiments totaling ≥12 
mice/condition. ***, P=0.006 unpaired Student’s t test. Error bars represent SEM. 
 
Most lung memory CD8 T cells are capillary-associated after infection 
Our results thus far indicate that the vast majority of transferred CD8 T 
cells recovered from perfused lung were actually present within the narrow 
capillary network associated with alveoli. We next sought to determine what 
proportion of memory CD8 T cells recovered from the lungs of infected mice 
were within blood. To this end, we generated P14 immune chimeras using an i.p. 
route of infection. We found that >96% of LCMV-specific CD8 T cells isolated 
from the lung were labeled with intravascular Ab (Figure 2-7). To determine 
whether this vascular-biased localization was unique to an i.p. infection, mice 
were instead infected via the intra tracheal (i.t.) route. Although local infection 
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established a significantly greater CD8 T cell response in the lung stroma and 
inducible bronchus-associated lymphoid tissue (iBALT), the majority of cells 
isolated from lung were still capillary-derived (Figure 2-7). 
 
Figure 2-7: Most lung memory CD8 T cells are capillary-associated after 
infection. P14 immune chimeras were infected with LCMV via the i.p. or i.t. 
route. 15 days later, mice were subject to intravascular staining and lymphocytes 
were isolated from perfused lung. Plots are gated on Thy1.1+ P14 cells. Data are 
representative of 2-3 independent experiments totaling ≥8 mice per condition. 
 
 Intratracheal infection with LCMV establishes infection in the lung  
LCMV is naturally transmitted between mice through a variety of routes 
including bites, social grooming, milk, nasal secretions, and airborne 
transmission (233, 242, 254, 262). To confirm that i.t. injection of LCMV was 
establishing a local respiratory infection, spleen and lungs of C57Bl/6J mice were 
frozen prior to or two days after i.t. injection of LCMV and immunohistochemical 
analysis was performed with an Ab specific for LCMV (Figure 2-8).  
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Figure 2-8: Intratracheal injection of LCMV establishes infection in the lung. 
Anti-collagen IV (green), -LCMV (red) and DAPI (gray) staining in the (A) spleen 
and (B) lung of C57Bl/6J mice before or two days after i.t. LCMV infection. 
Images are representative of 2 independent experiments totaling 4 mice. Scale 
bars represent 100µm. 
 
 After infection, mice inoculated i.p. maintained a constant proportion of 
P14 CD8 T cells in the lung tissue vs. capillaries. In contrast, i.t. infected mice 
experienced a dynamic elevation and contraction in the proportion of P14 CD8 T 
cells within lung tissue relative to capillaries (Figure 2-9 A), correlating with the 
transient presence of iBALT (data not shown). In spleen, P14 CD8 T cells initially 
predominated in red pulp, then gradually shifted to white pulp (Figure 2-9 B), 
correlating with TCM differentiation (113, 155, 229). 
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Figure 2-9: The proportion of antigen-specific T cells in lung tissue and 
splenic red pulp decreases over time. P14 immune chimeras were infected 
with LCMV via the i.p. or i.t. route. 15 days later, mice were subject to 
intravascular staining and lymphocytes were isolated from perfused lung. (A) 
Frequency of P14 cells that were protected from intravascular staining isolated 
from lung or (B) spleen after i.p (black) or i.t. (red) infection. Proportion of naïve 
(CD44lo) CD8 T cells (gray) that were protected from intravascular staining was 
also determined in spleen. Data are representative of 2-3 independent 
experiments per time point totaling ≥8 mice per condition. ***, P=0.0003; **, 
P<0.006 unpaired Student’s t test. Error bars represent SEM. 
 
Differential phenotype of lung tissue and vascular CD8 T cells 
We then examined the phenotype of P14 CD8 T cells 15 days after i.t. 
LCMV infection. P14 cells present in peripheral blood bore a striking 
resemblance to those cells isolated from the lung that stained with injected Ab 
(Figure 2-10 A-D, rows 1 and 2). In contrast, cells protected from i.v. staining 
were distinct, contained subsets of CD103 and CD69+ cells, and were uniformly 
CXCR3+ (Figure 2-10 A-D, rows 2 and 3). Airway T cells (removed prior to lung 
digestion) exhibited a distinct phenotype, including pronounced down-regulation 
of CD11a as previously described (Figure 2-10 A-D, rows 3 and 4) (155, 180). 
P14 CD8 T cells isolated from the liver or small intestine epithelium that were 
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protected from i.v. staining (~5% or >99% of total P14s isolated from each tissue, 
respectively, data not shown) were also uniformly CXCR3+ but were distinct from 
lung tissue cells in many respects (Figure 2-10 A-D, rows 5 and 6). 
Figure 2-10: Blood and tissue compartments of non-lymphoid tissues 
contain CD8 T cells with distinct phenotypes. The phenotype of P14 cells was 
evaluated in the indicated tissues 15 days after i.t. LCMV infection. Data are 
representative of 2-3 independent experiments per time point totaling ≥8 mice 
per condition. 
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Discussion 
A previous report quite elegantly demonstrated that CD8 T cells stimulated 
in vitro under varying conditions, and then transferred i.v., were differentially 
labeled by intravascular staining when recovered from lung, and exhibited distinct 
homing requirements (234, 263). Our study validates that intravascular staining 
discriminates between CD8 T cells present within the lung tissue from those 
trapped in the vasculature. We utilized this approach to re-evaluate the anatomic 
distribution of CD8 T cells isolated from lung after in vivo infection. This analysis 
revealed the major finding that, in some contexts, up to 96% of effector or 
memory T cells isolated from lung represent cells in the capillary vessels rather 
than lung tissue. Unique phenotypic signatures were expressed among cells 
protected from labeling, including CD69 and CD103/β7 integrin expression, 
which has been associated with resident TEM populations (120, 122, 155, 228, 
264). Moreover, only a small fraction of memory CD8 T cells transferred into 
naïve recipients that were recovered from lung actually migrated into the tissue. 
This process was chemokine dependent, and naïve T cells were excluded. 
These results precipitate a re-evaluation of previous studies that examined the 
distribution, phenotype, and homing requirements of pulmonary T cells, and also 
have ramifications for T cell-dependent protection studies that may overestimate 
localization of transferred or established T cell populations within lung tissue 
(113, 235, 265). The development of vaccine modalities that enhance true T cell 
homing to lung tissue, which may be evaluated by intravascular staining, may 
enhance protection against respiratory infections (124, 236, 237, 266, 267). 
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In summary, our results demonstrate that intravascular staining is a useful 
tool to define vascular and tissue pulmonary lymphocytes, indicate that the 
majority of T cells are often within the vasculature of perfused lung, and support 
a revised model of the regulation of cellular immunity within the respiratory 
mucosa. 
 
Materials and Methods 
Mice and infections 
P14 chimeric immune mice were generated as described (155, 254). Mice were 
either infected intraperitoneally (i.p.) with 2 x 105 PFU LCMV or intratracheally 
(i.t.) with 1 x 105 PFU LCMV (107-109, 111, 238). The University of Minnesota 
IACUC approved all experiments. 
Intravascular staining and cell isolations 
3 µg of Anti-CD8α-APC or anti-CD8α-PE (clone: 53-6.7 from eBioscience) or 
purified rabbit anti-mouse collagen IV (Novus Biologicals) were injected 
intravenously (i.v.). Three minutes later, the animals were sacrificed, lavaged to 
remove cells in the airway, bled, and perfused with 10 ml of cold PBS. The 
spleen, LNs, lung, liver, and small intestine were harvested within 12min, and 
lymphocytes were isolated as described (138, 268). Immunofluorescence 
staining was performed as described (155, 269-273). 
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Pertussis Toxin Treatment 
Purified splenocytes from P14 immune chimeric mice or naïve P14 transgenic 
mice were incubated in RPMI containing 10% FBS +/- 25 ng/ml pertussis toxin 
(R&D Systems) at a concentration of 1.5x107 cells/ml for 1h at 37°C as described 
(119, 256-258, 274).  Following incubation, 1.5-3.5x107 cells were injected i.v. 
into C57Bl/6 recipient mice. 
Immunofluorescence Microscopy 
Immunofluorescence staining was performed as described (122, 124, 155, 251, 
252). Briefly, tissues were frozen in O.C.T. on dry ice. 7µm frozen sections were 
cut using a Leica cryostat. Slides were fixed in cold acetone for 10 minutes. Prior 
to staining, slides were rehydrated for 10 minutes in PBS. All slides were blocked 
for 60-90 minutes with 5% bovine serum albumin (BSA) in PBS. Purified pAb 
goat anti-collagen type IV (AB769, Millipore), rat anti-LCMV nucleoprotein (VL-4, 
Bioxcell), or conjugated mAb anti-CD31-AF647 (clone: 390, Biolegend), anti-
CD31-AF488 (clone: MEC13.3, Biolegend), anti-CD90.1-AF647 (Thy1.1, clone: 
OX-7, Biolegend), anti-CD8β-AF647 (clone: YTS156.7.7, Biolegend), anti-CD4-
AF647 (clone: RM4-5, BioLegend) or anti-CD90.1-eF450 (Thy1.1, clone: HIS51, 
eBioscience), were used for primary staining. Primary antibodies were used for 
60 minutes at room temperature. Goat anti-rabbit AF488, goat anti-rabbit AF555, 
donkey anti-goat AF488, donkey anti-goat AF555, and donkey anti-rat AF488 
(Invitrogen) or donkey anti-rabbit AF647 (Jackson Immuno Research 
Laboratories) were used for secondary staining. Secondary antibodies were used 
for 30 minutes at room temperature. DAPI staining was performed for 10 
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minutes. Cover slips were mounted with Prolong Gold Anti-Fade mounting 
reagent (Invitrogen). A Leica DM5500B epifluorescent microscope with Leica 
Acquisition Suite Advanced Fluorescence software was used for image 
acquisition. Adobe Photoshop was used for image analysis. 
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Chapter 3 
 
Intravascular staining for essential discrimination of 
vascular and tissue leukocytes 
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Characterizing the cellular participants in tissue immune responses is 
critical for understanding infection, cancer, autoimmunity, allergy, graft rejection, 
and other immunological processes. Leukocytes recirculate through blood 
vessels before localizing to tissue sites of immune responses. Thus, in 
experimental animal models, tissues are often perfused to putatively remove 
blood-borne leukocytes that may conflate analysis. Here, we show via 
intravascular staining that perfusion both fails to remove many blood-borne 
leukocytes and also may remove tissue-localized populations of interest. We 
provide examples of how this issue distorts interpretation of tissue leukocyte 
composition and phenotype in healthy mice, as well as those responding to viral 
or Mycobacterium tuberculosis infection or tumor challenge. This study highlights 
the breadth and gravity of this issue, outlines simple methods for identification of 
various intravascular leukocyte populations, and demonstrates that these 
methods should be routinely adopted in lieu of perfusion for interpretable 
analyses of immune responses in many tissues. 
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Introduction 
Cells of the immune system act locally to ameliorate, prevent, or 
exacerbate disease (136, 244-247, 275). Thus, immune responses must be 
characterized directly within affected tissues. However, cells of the immune 
system also continuously recirculate throughout the vasculature, which includes 
an abundant capillary network that permeates every organ. Immune cells in 
blood, compared to those in tissues, exhibit vastly different phenotypes, 
functions, and differentiation states (247-253, 276-278). Those within blood are 
typically (although not always) recirculating cells rather than participants in local 
immune responses. Thus, blood-borne cell contamination of tissues significantly 
confounds the identification and purification of leukocytes that are truly 
participating in local immunological processes. A common solution to this 
problem in animal models is the putative removal of blood-borne leukocytes by 
perfusing tissues with a cell-free solution post mortem. 
 We recently utilized an intravascular staining approach (234, 279) and 
demonstrated that perfusion fails to remove many CD8 T cells from the lung 
vasculature during the course of an anti-viral response (177, 254, 280). Rather 
unexpectedly, up to 97% of the CD8 T cells that were thought to be located 
within the lung were not in the tissue (253, 254, 281), an observation that 
questions the interpretation of previous studies on CD8 T cell migration, 
differentiation, maintenance, and correlates of protective immunity against 
respiratory infections. 
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The present study addresses whether vascular contamination is an issue 
in other perfused tissues besides the lung and whether vascular populations 
conflate interpretation of the other major lineages of the adaptive and innate 
arms of the immune system. Negative consequences of perfusion are revealed. 
The strengths and weakness of different staining strategies for different leukocyte 
subsets and for different tissues are documented, and new intravascular staining 
applications are defined. Moreover, this study demonstrates that all future 
analyses of all immune cell lineages in tissues should dispense with perfusion 
and substitute intravascular staining, for which straightforward methods are 
described. 
Applications of the Method 
Discriminating between tissue-localized and blood-borne cells is relevant 
for studies examining cellular processes in non-lymphoid tissues. Our protocol 
outlines methods of intravascular staining for identification of vascular T and B 
cells, neutrophils, and mononuclear phagocytes in mice. Since cells in blood 
borne compartments may also play important roles in immune responses (177, 
255-258), intravascular staining may also be useful for those interested in 
including these populations of cells in analyses rather than eliminating them via 
perfusion.   
 Intravascular staining can be applied to studies of viral and bacterial 
infections as well as solid tumors in mice, but investigations of many other 
diseases processes, such as models of graft versus host disease, allergy and 
autoimmunity, as well as studies of cell migration, may also greatly benefit from 
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this type of analysis. While our research was limited to immune responses in 
mice, this protocol may be adaptable to other species, and additional applications 
and refinements are likely to develop as intravascular staining is applied to 
different settings. 
Comparison with other Methods  
Previous work examining neutrophil migration through the lung 
vasculature demonstrated that neutrophils transited the large vessels of the lung 
in ~3min, but required 3h if routed through the capillary bed (101, 177). As a 
result, the ratio of neutrophils:RBCs in lung capillaries is 100-fold higher than in 
peripheral blood or large lung vessels (1:100 vs. 1:10,000). Consequently, even 
though capillaries only comprise 40% of the blood volume of the lung, they 
contain 99% of the lung blood-borne neutrophils. These data indicate that 
hemodynamic forces greatly influence the transit rate of leukocytes in the 
microvasculature. Such forces may sequester lymphocytes within pulmonary 
vasculature as well, perhaps due to the expression of adhesion molecules or the 
fact that the volume of a lymphocyte is greater than an RBC (~290 femtoliters (fl) 
vs. ~90 fl) (259, 261, 282, 283).  
Perfusion, a method of flushing the pulmonary vasculature with buffer, has 
been used to remove RBCs and leukocytes from the lung vasculature. However, 
we recently showed that the vast majority of CD8 T cells isolated from the lung of 
perfused mice were likely trapped within the vasculature because they were 
rapidly stained with i.v. injected monoclonal antibody (mAb) (221, 254). These 
results call into question several studies reporting that naïve lymphocytes are 
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present within the lung tissue of specific pathogen free (SPF) mice that lack 
inducible bronchus associated lymphoid tissue (iBALT) (107-109, 111, 284, 285): 
observations that violate the central dogma that naïve lymphocytes are excluded 
from non-lymphoid tissues (NLTs) and which were proposed to have major 
biological implications. Here, we show how intravascular staining can be 
employed to address these issues. 
Experimental Design 
When incorporating intravascular staining, critical staining controls must 
be included in every experiment. Peripheral blood (from retro-orbital or cardiac 
puncture) should be sampled from every mouse. One should observe that >99% 
of the cell population targeted by the intravascular Ab will stain positively within 
the peripheral blood. A negative staining control, such as lymph nodes, should 
also be sampled. One should observe less than 10% of cells isolated from lymph 
nodes staining positively with intravascular Ab. For a discussion of Ab selection, 
see Figure 3.  
Limitations 
We have used intravascular injection of anti-collagen type IV Ab to test for 
vascular leakage in all the models examined in this manuscript. While the 
conditions we tested allow for reliable intravascular staining, there could be 
conditions under which vascular leakage may compromise the integrity of 
staining. For instance, there may be inflammatory contexts or angiogenic tumor 
models that allow rapid exudation of Ab into tissues, which could compromise 
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interpretation of intravascular staining. Investigators examining unique conditions 
would be advised to perform appropriate validating controls, such as histological 
analysis after injection of anti-collagen Ab or injection of Evans Blue Dye (EBD), 
as described (221, 242, 254, 262). A collagen basement membrane surrounds 
endothelial vessels in tissues such as the lung and intestine and is not exposed 
to intravascular Ab under conditions that we have tested. Collagen staining in the 
liver sinusoids, glomerular capillaries of the kidney, and red pulp of the spleen 
can be used as positive staining controls, as these are exposed to vascular Ab 
under steady state conditions (data not shown and Anderson et. al., 2012). As an 
alternative approach, one could consider using Evans Blue dye, as described. 
Evans Blue dye stains the serum protein albumin, which is only found in blood 
vessels under conditions with intact endothelium, but which permeates into 
tissues when vascular permeability is increased. Histological analysis or a 
quantitative comparison of EBD levels in sample tissues compared to healthy 
controls can be used to validate the appropriateness of intravascular staining. 
 
Intravascular Staining Procedure 
The sample preparation and flow cytometry acquisition steps described in 
the following procedure are for CD8αβ T cells isolated from a spleen, as an 
example application. 
 
1. Prepare Ab dilution in sterile 1x DPBS and keep on ice. For most procedures, 
3µg of Ab in 300µl of DPBS per mouse is sufficient. If the Ab is conjugated to a 
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fluorescent molecule, protect from light. Titration of untested Ab clones or 
fluorochromes is recommended prior to performing large experiments. 
CAUTION: do not dilute the Ab in buffer containing sodium azide, as high azide 
concentrations are toxic. 
2. Inject 300µl of Ab dilution intravenously into a mouse via the tail vein.  
3. Kill the mouse 3 min after injection using isoflurane. Euthanasia with inhaled 
isoflurane should be performed in a closed container with an absorbent material 
soaked in the anesthetic (the amount of isoflurane to use will vary with 
container size). Avoid contact between the mouse and the anesthetic.  
CRITICAL STEP: Longer wait times have not been validated. 
CAUTION: Isoflurane (2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane) is 
used for inhalational anesthesia. It is liquid at room temperature and vaporizes 
readily. Isoflurane is a powerful anesthetic and should always be used inside a 
laminar flow hood. Only approved containers should be used for euthanasia 
with inhaled anesthetics. 
CAUTION: Isoflurane euthanasia should be approved by an Institutional 
Animal Care and Use Committee and Institutional Biosafety Committee. 
4. Harvest tissues of interest into appropriate containers (petri dishes, conical 
tubes, or gentleMACS tubes, etc.) containing RPMI + 5% Fetal Bovine Serum 
(FBS).  
CRITICAL STEP: mouse euthanasia and tissue harvest should be performed 
quickly to improve cell viability. 
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5. Immediately smash or mince tissues and wash to rinse free or dilute any 
excess Ab. Store in RPMI + 5% FBS on ice.  
PAUSE POINT: Tissue pieces can be left on ice while additional mice are 
processed for up to 3 hours, although empirically, faster processing yields 
better results.  
6. If desired, isolate leukocytes from tissues. Numerous protocols have been 
described and vary depending on the tissue and leukocyte population of 
interest (155, 229, 286, 287). These protocols will not be reviewed here. Each 
investigator should optimize this protocol for the tissue and cell type of interest. 
Alternatively, organs may be embedded in freezing medium such as O.C.T. 
medium for subsequent immunohistochemical analysis (124, 155, 234, 243, 
254, 288).  
 
Sample preparation and analysis 
7.  Smash spleen and filter through a 70 µm nylon cell strainer to remove clumps. 
In parallel, process cells suitable for use as controls. 
CRITICAL STEP: Compensation controls should be prepared using either 
compensation particles or cells from an animal that did NOT receive 
intravascular antibody because injected animals will already contain fluorescent 
Ab.    
CRITICAL STEP: CD8αβ T cell isolation from spleen is described here as a 
typical example.  Adapt this protocol to the cells and tissue of interest to you. 
8.  Spin down the cells at 550 x g for 5 minutes. Pour off supernatant. 
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9.  Resuspend pellet of cells by vortexing. Lyse the red blood cells with 2 mL Ack 
lysis buffer for 2 minutes at room temperature. Add 10 mL RPMI + 5% FBS to 
dilute Ack lysis buffer. 
10.  Spin down the cells at 550 x g for 5 minutes. Remove supernatant. 
Resuspend cells in desired volume of FACS buffer and aliquot cells into 96-well 
round bottom plates.  
11.  Stain cells with ex vivo Abs, diluted as indicated in Table 1 in FACS buffer, 
for 30 minutes on ice. 
CRITICAL STEP: Do not add ex vivo Ab conjugated to the same fluorochrome as 
the Ab that was injected i.v. 
Fluorochrome Marker Ab clone Company Dilution 
PE CD44 IM7 eBioscience 2 µg/ml 
(1:100) 
PerCP-Cy5.5 CD8β YTS156.7.7 BioLegend 2 µg/ml 
(1:100) 
APC-eF780 CD62L MEL-14 eBioscience 2 µg/ml 
(1:100) 
Aqua Live / dead - Invitrogen Per protocol 
APC CD8α i.v. 53-6.7 eBioscience - 
Table 3-1: Sample CD8ab T cell ex vivo staining panel 
12.  Dilute stain with 150 µl FACS buffer and spin plate at 858 x g for 2 minutes 
to wash cells. Repeat wash twice. Resuspend in 200 – 300 µl FACS buffer for 
acquisition. 
PAUSE POINT: Cells can be fixed in 2% paraformaldehyde for 30 minutes, 
washed with FACS buffer (as in Step 12) and stored at 4°C in FACS buffer for 
up to 48 hours prior to acquisition. 
58 
Data Acquisition and Analysis Procedure 
CAUTION: Flow cytometry should be performed by trained individuals and in 
accordance will all institutional biosafety regulations. Refer elsewhere for 
detailed overviews of flow cytometry acquisition (241, 263) and data analysis 
(254, 264).  
13.  Prepare an acquisition template in the flow cytometry software (e.g. BD 
FACSDiva software) containing the fluorescent parameters in the staining 
panel. 
14.  Perform compensation using an unstained control and single-stained 
samples. 
15.  Prepare an acquisition layout containing the following plots:  
FSC-A vs. SSC-A – create a lymphocyte gate (“lymphocyte” population) 
SSC-A vs. SSC-W – display “lymphocyte” population and create a singlet gate 
(“singlets” population) 
CD8β vs. live/dead – display “singlets” population and create a CD8β+ live/dead- 
gate (“CD8β+” population) 
CD8α i.v. versus CD8β – display “CD8β+” population and create CD8α i.v.+ and 
CD8α i.v.- gates  
16.  Acquire 10,000 - 20,000 CD8β+ events and export FCS files for analysis in 
flow cytometry analysis software (e.g. Tree Star FlowJo software). 
17.  In Flow Jo, create lymphocyte, singlet, live CD8β+ and CD8α i.v.+ and CD8α 
i.v.- gates as in step 15. 
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Step Problem Possible Reason Solution 
3 Cell type of interest in 
peripheral blood 
staining control is not 
>99% stained with i.v. 
injected Ab 
Poor intravascular 
injection, Ab did not 
circulate long enough, 
or method of sacrifice 
disrupted circulation of 
Ab 
Ensure that tail 
vein injections are 
performed 
correctly. 
 
Allow Ab to 
circulate slightly 
longer (3.5 – 4 
minutes) prior to 
euthanasia. 
 
Do not use 
cervical 
dislocation to 
euthanize mice. 
5 Cells isolated from 
peripheral blood have 
a higher staining 
intensity than the 
vascular fraction in 
non-lymphoid tissues. 
Excess Ab was not 
diluted out immediately 
or too much Ab was 
injected. 
Dilute peripheral 
blood immediately 
after removal. 
 
Reduce 
concentration of 
Ab to inject. 
5 Tissues with low 
vasculature:tissue 
ratios have very high 
intravascular staining 
frequencies or MFI 
when compared to 
negative control 
samples. 
Excess Ab was not 
rinsed off immediately. 
Proceed to rinsing 
tissues faster 
during the 
harvesting 
process. 
Table 3-2:  Troubleshooting Tips 
 
Sample preparation and acquisition steps for examining vascular 
permeability of the lung.  
CAUTION: Microscopy should be performed by trained individuals and in 
accordance will all institutional biosafety regulations. Refer elsewhere for 
detailed overviews of immunofluorescence staining (254, 265) and microscopy 
(266, 267, 289). 
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1.  Follow intravascular staining protocol steps 1-4 using purified polyclonal goat 
anti-mouse collagen type IV (15µg/mouse). As a control, include a sample slide 
for ex vivo anti-Collagen type IV staining. One of the following should be 
included as a positive control for intravascular Collagen type IV staining: liver 
sinusoids, glomerular capillaries of the kidney, or red pulp of the spleen.  
2.  Embed the lung and spleen in O.C.T. medium.  
3.  Snap freeze samples in liquid nitrogen or on dry ice. 
4.  Prepare 7µm sections on microscope slides using a cryostat. 
5.  Fix slides in cold acetone for 10 min. 
PAUSE POINT: Slides can be stored at -20°C or -80°C for at least 18 months. 
6.  Rehydrate slides with 1x DPBS for 10 minutes. 
7.  Block slides for 60-90 minutes at room temperature (or overnight in the fridge) 
with 5% BSA Blocking solution. 
8.  Stain slides with mAb anti-CD31-AF488 for 60 minutes (dilute anti-CD31 Ab 
1:100 in 5% BSA Blocking solution or PBS). The control slide should also be 
stained with purified polyclonal goat anti-mouse collagen IV (dilute anti-
Collagen IV Ab 1:200 in 5% BSA Blocking solution or PBS). 
9.  Wash slides gently 3 times with 5% BSA Blocking solution or PBS. 
10.  Stain slides with purified polyclonal donkey anti-goat-AF555 for 30 minutes 
(dilute anti-goat Ab 1:2000 in 5% BSA Blocking solution or PBS).  
11.  Wash slides gently 3 times with 5% BSA Blocking solution or PBS. 
12.  Stain slides with DAPI for 10 minutes. 
13.  Wash slides gently with 5% BSA Blocking solution or PBS. 
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14.  Gently tap or blot off excess 5% BSA Blocking solution and mount coverslips 
onto slides with Prolong Gold Anti-Fade mounting reagent. 
15.  Acquire images using a Leica DM5500B epifluorescence microscope with 
Leica Acquisition Suite Advanced Fluorescence software.  
Timing 
From the time of Ab injection until organ isolation may take 5 - 30 minutes per 
mouse, depending on the number of organs harvested and the experience of the 
investigator. This does not include subsequent isolation of leukocytes, staining 
and analysis.  
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Results 
Evidence that perfusion should be avoided 
We recently showed that the vast majority of memory CD8 T cells isolated 
from the lung of perfused mice were likely trapped within the vasculature 
because they were rapidly stained with i.v. injected monoclonal antibody (mAb) 
(254). To confirm previous reports regarding the presence of naïve T and B cells 
within the lung tissue(107-109, 111, 177), we isolated B cells and T cells from the 
lungs of uninfected mice that were perfused to remove blood from organs. 
Consistent with what has been published, the majority of lymphocytes isolated 
from lung did in fact express a naïve phenotype (CD62L+ and CD44lo for T cells 
and IgD+ and/or IgM+ for B cells). Importantly, when anti-CD45.2 mAb was 
injected i.v. three minutes before mice were sacrificed and perfused (CD45 is 
expressed on the surface of all leukocytes), >99% of naïve lymphocytes, 
regardless of lineage, became labeled (Figure 3-1). We hypothesized that 
intravascular labeling indicates that cells were confined to the vasculature of 
mice despite perfusion. 
63 
 
Figure 3-1: Naïve lymphocytes isolated from the lung are confined to the 
vasculature despite perfusion. Anti-CD45.2 mAb was injected i.v. via the tail 
vein of naïve C57Bl/6 mice three minutes before perfusion and lymphocyte 
isolation. Naïve CD4+ and CD8+ T cells and B cells were identified by flow 
cytometry as indicated and examined for labeling with injected anti-CD45.2 mAb. 
Representative of 12 mice from two experiments. 
  
After local LCMV infection, iBALT, a transient tertiary lymphoid organ, 
appears in the lung. iBALT has been well characterized and is classically defined 
as a collection of lymphocytes and dendritic cells that abuts a large airway, is 
typically adjacent to large blood vessels, and contains both lymphatic vessels 
and high endothelial venules (HEV, as detected by Peripheral Node Addressin 
(PNAd) staining) (268, 282, 283). We discovered that LCMV infection also 
induced abundant lymphocyte aggregates that were distinct from iBALT in that 
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they lacked HEVs, were much smaller, and were not located near large airways. 
Interestingly, perfusion significantly reduces the abundance of iBALT and 
alveolar lymphoid aggregates detectable per lung lobe (Figure 3-2), and 
appeared to reduce the cellularity of those that remained (data not shown). 
Indeed, alveolar lymphoid aggregates were difficult to detect after perfusion, 
which may help explain why they have rarely been noted previously (155, 269-
273).  
Figure 3-2: Perfusion depletes cells from lung tissue. 15d after i.t. LCMV 
infection, lungs from P14 chimeras were perfused or left unperfused. 
Representative immunofluorescence images of iBALT or aggregate structures in 
lungs stained with anti-collagen type IV (green), -PNAd (red), -Thy1.1 (gray) and 
DAPI (blue). Arrow designates PNAd+ high endothelial venule. Scale bars = 
100µm. Representative of two experiments totaling 10 mice per condition. * p = 
0.05. ** p < 0.01. Error bars indicate SEM. 
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Collectively, these data show that perfusion not only leaves behind 
abundant vascular-bound lymphocytes, but also depletes tissue cells and 
structures that may be of interest.  
Validation of intravascular staining 
In lung, confocal and epifluorescence microscopy shows that lymphocytes 
stained with intravascular Ab are present within the vasculature (Figure 3-3).  
 
Figure 3-3: Intravascular staining is confined to vascular cells. Anti-CD31 
and anti-CD45.2 or (c-g) anti-CD45.2 mAb alone was injected i.v. into C57Bl/6 
mice 12d after i.t. LCMV infection. (b) Confocal imaging of lung, anti-CD31 i.v. 
(green), -CD45.2 i.v. (red), –CD8β (cyan) and DAPI (gray). Representative of 
three experiments totaling 4 mice. 
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Cells stained with i.v. mAb were truly confined to CD31+ vessels, whereas cells 
protected from the i.v. mAb were present outside of capillaries, including the 
pulmonary epithelium, iBALT, airway lamina propria, surrounding large blood 
vessels, as well as pericapillary and lung airway compartments (Figure 3-4 A-C, 
data not shown). These data demonstrate that CD8 T cells stained with 
intravascular Ab within the lung are confined to vasculature and CD8 T cells 
protected from intravascular staining are outside of vasculature. 
 
Figure 3-4: CD8 T cells in iBALT, alveolar lymphoid aggregates and 
epithelium are not accessible by intravascular Ab. (A) iBALT, (B) alveolar 
lymphoid aggregates, and (C) intraepithelial lymphocytes (IEL) in the lung 12d 
after i.v. LCMV infection. Orange arrows indicate sample IELs. Data 
representative of three experiments totaling nine mice. 
 
While perfusion fails to completely remove “contaminating” vascular 
lymphocytes from many tissues (Figure 3-1), it should also be noted that vascular 
lymphocytes populations are also often of interest (155, 256-258, 274). For 
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example, histological examination of the lymph nodes of mice that were not 
perfused confirms that i.v. mAb labeled CD8 T cells are largely contained within 
HEVs (Figure 3-5), and likely represent marginated cells preparing for lymph 
node (LN) entry. Thus, intravascular staining may be a useful approach to 
identify this population for further characterization. Permissiveness to 
intravascular Ab labeling in additional tissues will be shown in Figure 3-8. In 
summary, perfusion is unnecessary if intravascular staining is incorporated, and 
neglecting to perfuse has advantages. 
 
Figure 3-5: Intravascular staining in lymph nodes is confined to HEVs. (A) 
Inguinal lymph node sections showing anti-CD45.2 i.v. mAb staining (red) and ex 
vivo anti-CD31 (cyan), -CD8β (green), and DAPI (gray). (B) White inset from A 
without DAPI displayed. Yellow arrows indicate anti-CD45.2 i.v. and -CD8β mAb 
co-staining. Scale bars represent 100µm. Data representative of three 
experiments totaling nine mice. 
 
Intravascular staining without perfusion is sufficient to reveal unique 
lymphocyte subsets in tissues 
We next questioned whether perfusion was necessary if intravascular 
staining was utilized. This issue was examined in the context of polyclonal 
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endogenous CD4 and CD8 T cell responses twelve days after i.t. LCMV 
infection. H-2Db/gp33 MHC I tetramers and I-Ab/gp66 MHC II tetramers were 
used to identify LCMV-specific CD8 and CD4 T cells responses, respectively 
(Figure 3-6A). In this case, vascular T cells were identified via injection of anti-
CD45.2 mAb, but mice were not perfused. All examined tissues contained 
LCMV-specific CD4 and CD8 T cells that were labeled by i.v. injected mAb 
(Figure 3-6, 3-7 and data not shown). However, all cells in non-lymphoid tissues 
that labeled with vascular injected mAb were contained within endothelial 
vessels, as confirmed by immunofluorescence imaging (Figure 3-8). 
Of note, CD69+ T cells were only found in the compartment of NLT 
protected from the i.v. mAb, with the exception of cells isolated from the liver. 
CD69 has been proposed to be a marker of tissue resident T cell populations 
(114, 122, 124, 143, 155, 251, 252), and these results suggest that liver may 
contain a fraction of sinusoidal resident CD8 T cells. CD69 expression profiles in 
tissues were similar 12 and 30 days after infection (data not shown). The 
proportion of i.v. protected LCMV-specific CD4 T cells in tissues was typically 
greater than observed for CD8 T cells, particularly in lung (Figure 3-7).  
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Figure 3-6: Intravascular staining without perfusion is sufficient to reveal 
unique lymphocyte subsets in tissues. C57Bl/6 mice were injected with anti-
CD45.2 mAb i.v. 12 days after i.t. LCMV infection. Lymphocytes were isolated 
and LCMV-specific CD4+ and CD8+ T cells were identified with I-Ab/gp66-77 and 
H2-Db/gp33-41 MHC tetramers, respectively. (A) Representative tetramer staining 
in spleen. Anti-CD45.2 i.v. and anti-CD69 mAb staining of (B)  H2-Db/gp33-41-
gated CD8 or (C) I-Ab/gp66-77 CD4 T cells isolated from the indicated 
compartments. Data are representative of at least 9 mice from 3 independent 
experiments. 
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Figure 3-7: Intravascular staining profile of endogenous LCMV-specific CD8 
and CD4 T cells isolated from several unperfused tissues. Frequency of 
tetramer positive cells protected from i.v. mAb staining in lung. Data are 
representative of at least 9 mice from 3 independent experiments. **** p < 
0.0001. Error bars indicate SEM. 
 
Technical considerations for intravascular staining 
We next examined practical combinations of mAb clones for intravascular 
staining. When tracking adoptively transferred CD8 T cells in mice, such as P14 
T cells, vascular populations can be readily detected by i.v. injection of anti-CD8α 
mAb (clone 53-6.7), followed by ex vivo staining of all isolated populations via 
anti-CD8β mAb (clone YTS156.7.7, Figure 3-9A). This approach takes 
advantage of the fact that most CD8+ T cell populations express heterodimeric 
CD8 consisting of both α and β chains. For tracking CD4 T cells (CD4 consists of 
a single chain), two anti-CD4 mAb clones that do not compete for the same 
binding sites are optimal. For example, this can be achieved by i.v. injection of 
anti-CD4 mAb clone RM4-4 followed by ex vivo staining with clone RM4-5 
(Figure 3-9B). Alternatively, a mAb specific for CD45 (Figure 3-9C), a pan- 
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Figure 3-8: Imaging intravascular staining of leukocytes in unperfused 
tissues. C57Bl/6 mice were injected with anti-CD45.2 mAb i.v. 12d after i.t. 
LCMV infection. (A,B) Salivary gland, (C,D) female reproductive tract, (E-G) 
small intestine, and (H,I) large intestine sections showing anti-CD45.2 i.v. mAb 
staining (red) and ex vivo DAPI (gray), anti-cytokeratin 8 and -cytokeratin 18 
(green), and -CD31 (cyan) staining. Scale bars represent 100µm. All data are 
representative of three experiments from nine mice. 
 
leukocyte marker, is useful if contemporaneously examining multiple leukocyte 
lineages in one mouse or if the use of anti-CD8β must be avoided; for instance 
CD8β staining can block staining with peptide:MHC I tetramers (275, 290). In this 
case, we have used the same mAb clone for both intravascular and ex vivo 
72 
staining (anti-CD45.2 mAb clone 104). This strategy could be pursued for any 
marker (Figure 3-9D shows dual staining with the anti-CD8α clone 53-6.7 as an 
example), particularly when mAb clones are limited to markers of interest. 
However, this approach does diminish the intensity of the ex vivo staining, 
particularly in peripheral blood. While other mAb combinations may suit 
investigators’ unique goals, it is important to avoid i.v. injection of complement-
fixing mAb that may rapidly eliminate labeled cells. 
 
Figure 3-9: Technical considerations for intravascular staining. (A) Thy1.1+ 
P14 CD8 T cell chimeras, (B) CD45.1+ SMARTA CD4 T cell chimeras, or (C, D) 
CD45.2+ C57Bl/6 mice were infected with LCMV i.t. After 12-15 days, mice were 
injected i.v. with the indicated mAb (clones are in parentheses), sacrificed three 
minutes later, and lymphocytes were isolated and further stained ex vivo for flow 
cytometric analysis. Plots are gated on (A) CD8β+ and Thy1.1+, (B) CD4 (clone 
RM4-5)+ and CD45.1+, (C) CD45.2+ (clone 104, stained ex vivo), CD8α+, and 
H2-Db/gp33-41 MHC I tetramer+, (D) or CD8α+ (stained ex vivo) and H2-Db/gp33-41 
MHC I tetramer+ lymphocytes. Plots are representative of at least three 
experiments and nine mice per condition.   
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 When examining the spleen, intravascular staining discriminates between 
cells occupying red pulp (i.v. stain positive) and white pulp (i.v. stain negative, 
Figure 3-10). When injecting anti-CD45 mAb, the marginal zone is stained 
particularly brightly. However, among T cells, CD45 staining in splenic red pulp is 
less intense than the vascular compartments of other tissues (lung, for example) 
or peripheral blood (Figure 3-11). 
 
Figure 3-10: Immunofluorescence images of spleens after intravascular 
staining. After 12-15 days, mice were injected i.v. with the indicated mAb (clones 
are in parentheses), sacrificed three minutes later, and lymphocytes were tissue 
sections were examined by epifluorescence microscopy. mAb specific for 
collagen type IV (green) and CD8β or CD4 (cyan, as indicated) stained ex vivo, 
and the indicated i.v. injected mAb (red) on spleen sections. Images are 
representative of at least three experiments and eight mice per condition. Scale 
bars = 100µm. 
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Figure 3-11: Intravascular staining intensity differences in distinct organs. 
30d after i.t. LCMV infection of C57Bl/6 mice, anti-CD45.2 i.v. mAb staining 
intensity was examined on CD8α+ H2-Db/gp33-41 MHC I tetramer+ lymphocytes 
isolated from blood (PBL, red), spleen (blue), and lung (black). Representative of 
three experiments totaling nine mice. 
 
Intravascular staining indicates anatomic localization of B cells 
Our next study determined the extent to which intravascular staining could 
be applied to refine the anatomic compartmentalization of different B cell 
subsets. A thirteen parameter flow-cytometry panel was used to phenotypically 
identify Ab-secreting (Intracellular Ig high), B1 (B220 low, CD43+), germinal 
center (B220+, CD43 low, CD38 low, GL7+), switched memory (CD19+, B220+, 
CD38+, IgM/IgD-) or naïve and unswitched memory (CD19+, B220+, CD38+, 
IgM/IgD+) B cells after LCMV infection (Figure 3-12A).  
In the spleen, Ab-secreting and germinal center B cells were protected 
from i.v. anti-CD45.2 mAb (12 days after i.t. challenge with LCMV, Figure 3-12B 
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and D), consistent with preferential localization to white pulp follicles (276-278, 
291). Although B1, naïve, unswitched memory, and switched memory B cells 
were also predominantly protected from i.v. mAb staining, ~30% of each subset 
was exposed to i.v. mAb (Figure 3-12C, E-F). These data extend the applications 
of intravascular staining to B cells. 
Figure 3-12: Intravascular staining indicates anatomic localization of B 
cells. Anti-CD45.2 mAb was injected i.v. into C57Bl/6 mice 12 days after i.t. 
LCMV infection. (A) Gating strategy. Lymphocytes were isolated from spleen and 
anti-CD45.2 mAb staining was examined on the following B cell lineages that 
were identified by 13-parameter flow cytometry (defining markers indicated in 
parentheses): (B) Ab-secreting cells (intracellular Ig+, IgM-, IgD-), (C) B1 B cells 
(intracellular Ig+, CD19+, B220-, CD43+), (D) germinal center B cells 
(intracellular Ig+, CD19+, B220+, CD43-, CD38-, GL7+), (E) unswitched naïve 
and memory B cells (intracellular Ig+, CD19+, B220+, CD43-, CD38+, GL7-), or 
(F) isotype switched memory B cells (intracellular Ig+, CD19+, B220+, CD43-, 
CD38+, GL7-, IgM-, IgD-). Plots are representative of three experiments totaling 
nine mice. 
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Intravascular staining during Mycobacterium tuberculosis infection reveals 
tissue-specific myeloid and lymphoid cell subsets 
To examine the extent to which intravascular staining could delineate 
differences between vascular and tissue cells of the myeloid lineage, we used 
fourteen-parameter flow cytometry to measure markers characteristic of 
neutrophils (Ly6G, clone IA8) and mononuclear phagocytes (intracellular CD68+, 
these include monocytes, macrophages and dendritic cells, DCs) (Figure 3-13A). 
Neutrophils could be isolated from the lungs of naïve mice, regardless of 
perfusion (Figure 3-13B). This is surprising, as neutrophils do not occupy most 
healthy tissues. However, employing intravascular staining revealed that all of 
the isolated neutrophils from the naive lung were labeled with the i.v. mAb, 
suggesting that they were not in the pulmonary tissue of uninfected mice and that 
perfusion failed to remove them from vasculature (Figure 3-13C). Both i.v. mAb 
labeled and unlabeled CD68+ mononuclear phagocytes were recovered, 
consistent with the fact that certain myeloid cells are present both in blood and in 
tissue parenchyma and airways at steady state (238, 279)(Figure 3-13D). 
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Figure 3-13: Perfusion fails to remove myeloid cells from lung vasculature.  
(A) Gating strategy for myeloid neutrophils and mononuclear phagocytes. (B) 
Neutrophils and mononuclear phagocytes were recovered from the lungs of 
naïve C57Bl/6 mice with or without perfusion. Intravascular staining of (C) 
neutrophils or (D) mononuclear phagocytes from lungs of perfused (left plots) or 
unperfused (right plots) naïve mice. Representative of nine mice per condition 
from two independent experiments. 
 
 To confirm that bona fide pulmonary neutrophils would be protected from 
intravascular staining, we evaluated the i.v. staining technique in a situation in 
which neutrophils localize to lung tissue. Mycobacterium tuberculosis (Mtb) 
causes a chronic lung infection that is contained, but not eliminated, by local 
immune responses. 12 week old C57Bl/6 mice were infected with 100-150 CFU 
of aerosolized Mtb (strain H37Rv), anti-CD45.2 mAb was injected i.v. 24 days 
later, and leukocytes from the lungs, bronchioalveolar lavage (BAL) of the lung 
airways, and blood were evaluated. Unlike uninfected mice, approximately half 
the neutrophils recovered from lung were now protected from i.v. mAb (PBL and 
BAL served as positive and negative staining controls, respectively, Figure 3-14A 
A&B). Similarly, and consistent with enhanced recruitment of myeloid cells to the 
lung between three to four weeks after Mtb infection (177, 238, 280), the 
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proportion of unlabeled CD68+ mononuclear phagocytes also increased after 
Mtb infection compared to naïve mice (Figure 3-14C).  
 
Figure 3-14: Intravascular staining of myeloid cells isolated from PBL, BAL 
or lungs of C57Bl/6 mice 24d after Mtb infection without perfusion. (A) 
Neutrophils and mononuclear phagocytes isolated from lung 24d after infection 
with 100-150 CFU of aerosolized Mtb (strain H37Rv) were identified by staining 
for CD68 and Ly6G. Intravascular staining of (B) neutrophils or (C) mononuclear 
phagocytes isolated from blood (PBL), airways (BAL) or lung tissue. 
Representative of nine mice per condition from two independent experiments. 
 
Amongst CD68+ cells we then further discriminated various pulmonary 
myeloid subsets, such as inflammatory monocytes/macrophages (Ly6C+, 
CD11b+, CD11c-), conventional DC (cDC, CD11b+/- and CD11c+), tissue 
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resident CD103+ cDC (CD103+, CD11c+, CD11b-) and inflammatory monocyte-
derived DCs (moDC, Ly6C+, CD11c+ CD11b+) (168, 169, 253, 281). As 
expected, CD103+ cDCs isolated from the lung were indeed protected from 
intravascular mAb staining (Figure 3-15A&C). Interestingly, Ly6C+, CD11c- 
monocytes/macrophages were largely contained in the i.v. labeled fraction 
(Figure 3-15B&C) suggesting that the majority of this subset represents true 
monocytes present in pulmonary blood vasculature, while only a minority were 
tissue-localized bona fide macrophages. It should be noted that previously the 
Ly6C+, CD11c- population was found to be seemingly homogeneous with 
uniform expression of over 50 phenotypic markers of interest (122-124, 169, 177, 
292) (data not shown), highlighting the critical importance of the intravascular 
staining technique in distinguishing pulmonary Ly6C+ inflammatory monocytes 
from macrophages.  
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Figure 3-15: Intravascular staining during Mycobacterium tuberculosis 
infection reveals tissue-specific myeloid cell subsets. (A) CD11b and CD103 
or (B) CD11c and Ly6C staining on mononuclear phagocytes isolated from the 
indicated compartments. (C) Summary of CD68+ mononuclear phagocyte 
subsets as defined in A,B. Plots are representative of two experiments totaling 
nine mice. * p<0.05. **** p<0.0001. n.s. = not significant. Error bars indicate 
SEM. 
 
Moreover, inflammatory moDCs (CD11b+, CD11c+, Ly6C+) represent the 
major myeloid cell type truly present in the lungs of Mtb infected mice, since they 
were completely protected from i.v. mAb labeling (Figure 3-15B&C). These 
inflammatory moDCs have recently been shown to be highly multifunctional, 
producing IL-1α, IL-1β, TNFα, iNOS, and IL-10 and are phenotypically 
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characterized by high TLR2, CD13, Ly6C and CD64 expression (126, 177, 254, 
293). Thus, utilization of the intravascular staining technique uniquely enabled us 
to enrich and uncover inflammatory moDCs as myeloid effector cells in lung 
tissue in response to Mtb infection, another observation otherwise obscured by 
the presence of large numbers of myeloid cells in the lung blood vasculature. 
In the context of Mtb infection, intravascular staining also discriminated 
between the function and phenotype of local T cells truly within the lung as 
compared to those in vasculature (Figure 3-16 and data not shown). For 
example, intravascular staining revealed that I-Ab ESAT-61-20 and KbTB10.3/44-11 
tetramer+ T cells (which identify Mtb-specific CD4 and CD8 T cells, respectively) 
had profound differences in PD-1 expression, a receptor that inhibits T cell 
function and is regulated by antigen-stimulation (Figure 3-16 B&C).  Among both 
antigen-specific CD4 and CD8 T cells, PD-1 was more highly expressed on cells 
protected from intravascular staining compared to i.v. labeled cells present in 
vasculature (Figure 3-16 B&C). Taken together, these data clearly indicate that 
intravascular staining has the potential to change our understanding of local 
immune control over Mtb. 
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Figure 3-16: Intravascular staining without perfusion is sufficient to reveal 
unique lymphocyte subsets in lung tissue after Mtb infection. Mtb-specific 
CD4+ and CD8+ T cells isolated from lung 24d after infection with 100-150 CFU 
of aerosolized Mtb (strain H37Rv) were identified by staining with I-AbESAT-61-20 
and KbTB10.3/44-11 MHC tetramers, respectively. (A) Representative anti-CD45.2 
i.v. mAb and MHC tetramer staining. PD-1 expression on (B) CD4+ and (C) 
CD8+ T cells from lungs. Shaded histograms are anti-CD45.2 i.v. mAb-, and 
black line indicates anti-CD45.2 i.v. mAb+. (D) Geometric mean fluorescence 
intensity (geoMFI) of PD-1 expression on naïve (CD44lo) or Mtb MHC tetramer+ 
CD4 and CD8 T cells. Plots are representative of two experiments totaling nine 
mice. **** p<0.0001. n.s. = not significant. Error bars indicate SEM. 
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Intravascular staining reveals myeloid and lymphoid tissue-specific 
subsets in tumor-bearing tissue 
To determine the extent to which intravascular staining can distinguish 
tissue from vascular immune cells in a non-infectious disease model, we 
phenotypically analyzed T cells and myeloid cells in a solid tumor model of renal 
cancer (282, 283, 294). Murine renal adenocarcinoma cells (Renca) were 
injected into the left kidneys of 8 week old BALB/c mice. Tumor nodules were 
detectable histologically in the left kidneys 14 days later (Figure 3-17).  
 
Figure 3-17: Immunofluorescence imaging of renal adenocarcinoma tumor 
model in mouse kidney. Non-metastatic Renca cells were injected into the 
kidney of Balb/c female mice in order to establish solid tumors. After 14 days, 
kidneys were removed and sections were stained ex vivo for cytokeratin 8 and 18 
(green), collagen type IV (red), CD31 (cyan), and DAPI (gray). Scale bar = 
250µm. Representative of five mice analyzed from three experiments. 
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When a polyclonal Ab (pAb) against collagen was injected i.v., it labeled 
glomerular basement membrane, but did not infiltrate the tumor (data not shown), 
indicating that i.v. injected Ab staining was limited to vascular-localized epitopes. 
In separate mice, anti-CD45.2 mAb was injected i.v. and cells isolated from 
blood, tumor-bearing kidneys, and non-tumor-bearing contralateral kidneys were 
examined. Intravascular staining revealed striking phenotypic differences among 
T cells within tumor-bearing kidney compared to those in control kidney tissue 
and also blood (Figure 3-18). For instance, ~30% of CD4 T cells protected from 
i.v. mAb staining isolated from tumor-bearing tissue co-expressed CD69 and 
CD103, a phenotype suggestive of regulatory T cells that may interfere with 
tumor immune responses. The inhibitory molecule PD-1, which is expressed 
upon cognate Ag stimulation, was expressed by most CD45.2 unlabeled T cells 
in tumor-bearing kidneys. This observation provides further evidence that 
intravascular staining may be used to identify tumor-infiltrating lymphocytes.  
85 
 
Figure 3-18: Intravascular staining reveals lymphoid tissue-specific 
subsets in a murine renal adenocarcinoma model. Non-metastatic Renca 
cells were injected into the kidney of Balb/c female mice in order to establish 
solid tumors. Anti-CD45.2 mAb was injected i.v. 14d after intrarenal Renca cell 
injection. (A) CD69 and CD103 expression on CD4 and CD8 T cells isolated from 
PBL, tumor-bearing kidney, and contralateral kidney. Frequency of (B) 
CD69+/CD103+ CD4 T cells and (C) CD69+ CD8 T cells from tumor-bearing 
mice. (D) PD-1 expression on CD4 and CD8 T cells isolated from PBL (gray) and 
tumor-bearing kidney (anti-CD45.2 i.v. mAb+ in red and anti-CD45.2 i.v. mAb- in 
blue). * p < 0.05, ** p < 0.01, *** p < 0.0005, **** p < 0.0001. Error bars indicate 
SEM. 
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Myeloid-derived suppressor cells (MDSCs) are immature myeloid 
cells that can both suppress anti-tumor immune responses as well as promote 
cancer (221, 295). The presence and subsequent suppressive capacity 
of MDSC have been reported in both human renal cell patients and Renca 
murine models (126, 284, 285). Two main subsets of MDSC exist based on their 
Ly6G expression (168, 169, 221), which have been shown to be phenotypically 
and functionally distinct (180, 286, 287). Therefore, understanding where they 
reside within the tumor-bearing kidney can shed light on their functional 
capabilities and suppressive mechanisms. To determine whether certain subsets 
of MDSCs were more likely to be found in tumor-bearing kidney tissue or 
vasculature, we examined anti-CD45.2 i.v. mAb staining on CD11c- CD11b+ 
Ly6C+ MDSC subsets based on Ly6G expression (Figure 3-19). Ly6G+ MDSCs 
were predominantly found in Renca tumors whereas Ly6G- MDSCs were 
isolated from both tumor tissue and vasculature (Figure 3-19).  Together, these 
data suggest that intravascular staining is also a useful tool to refine our 
understanding of anti-tumor immune responses. 
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Figure 3-19: Intravascular staining reveals myeloid tissue-specific subsets 
in a murine renal adenocarcinoma model. Non-metastatic Renca cells were 
injected into the kidney of Balb/c female mice in order to establish solid tumors. 
MDSCs were isolated from tumor-bearing kidneys 14d after Renca cell injection. 
(A) Gating strategy for myeloid-derived suppressor cells (MDSCs). (B) CD45.2 
i.v. mAb staining of Ly6G- and Ly6G+ MDSCs are shown. (C) Percentage of 
Ly6G- and Ly6G+ MDSCs from tumor-bearing kidneys protected from CD45.2 
i.v. mAb staining. All plots are representative of 8-11 mice from three 
experiments.  * p < 0.05, ** p < 0.01, *** p < 0.0005, **** p < 0.0001. Error bars 
indicate SEM. 
 
Discussion 
Intravascular staining has previously been used to distinguish between 
single populations of leukocytes in the vascular circulation and those in the tissue 
of the lung (124, 180, 234, 243, 254, 288) or the red and white pulp of the spleen 
(180, 241). Moreover, perfusion was shown to inefficiently remove CD8 T cells 
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from the lung vasculature (254, 296-300). Here, we reveal the true scope of this 
issue by showing that cells of both the adaptive and innate immune system 
accumulate in the vasculature of many tissues and in the disease models 
examined. Perfusion not only fails to remove many vascular-bound leukocytes, 
but may also disrupt novel tissue populations such as alveolar lymphoid 
aggregates. Methods for intravascular staining in mice were delineated and 
validated. The strengths, considerations, and caveats of using different mAb 
combinations for studying various members of the innate and adaptive immune 
system were described. No specific problems with intravascular staining were 
encountered in any of the models presented. 
 These findings discourage the widely used practice of perfusion. Rather, 
they provide a compelling rationale for the incorporation of intravascular staining 
when possible, without perfusion, when studying any tissue leukocyte population. 
In fact, this approach may be absolutely necessary to capture an accurate and 
interpretable representation of the local participants in immune-mediated 
protection and disease.  
 
Materials and Methods 
Mice and Infections 
Specific pathogen free (SPF) C57Bl/6 mice from Jackson Laboratories were 
used for analysis of immune responses to infection. Thy1.1+ P14 chimeric mice 
were generated as described (254, 301-304). CD45.1+ SMARTA chimeric mice 
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were generated as described (289, 304, 305). Mice were infected intratracheally 
(i.t.) with 1 x 105 PFU LCMV (126, 254). C57Bl/6 mice were infected with 100-
150 CFU of aerosolized Mycobacterium tuberculosis (strain H37Rv) as described 
(123, 126, 177).  SPF Balb/c mice from the National Cancer Institute were used 
for analysis of immune responses to solid tumors. All animal experiments were 
approved by the Institutional Animal Care and Use Committee (IACUC) at either 
the University of Minnesota or the National Institutes of Health. 
Tumor cell line and challenge 
The murine renal adenocarcinoma cell line, Renca, was obtained from Dr. Robert 
Wiltrout (National Cancer Institute, Frederick, MD), and maintained in Complete 
RPMI. For intrarenal tumor challenge a skin incision was made on the left flank, 
and 2 x 105 Renca cells were injected through the intact peritoneum into the left 
kidney (282, 283, 294). 
Intravascular staining and cell isolations 
Intravascular Ab was injected intravenously (i.v.). Three minutes later, the 
animals were sacrificed, lavaged to remove cells in the airway, bled, and 
perfused (as indicated) with 10 ml of cold phosphate buffered saline (PBS). The 
spleen, lymph nodes, lung, liver, kidney, salivary gland, female reproductive tract, 
small and large intestine were harvested within 12min, and lymphocytes were 
isolated as described (126, 155).  
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Analysis Marker Fluorochrome Clone Company 
CD8 T cells CD8α APC 53-6.7 eBioscience 
 CD8α PE 53-6.7 eBioscience 
CD4 T cells CD4 FITC RM4-4 eBioscience 
Endothelium CD31 AF488 MEC13.3 Biolegend 
Collagen 
basement 
membrane 
Collagen IV N/A 
Purified Ab 
N/A 
Polyclonal goat 
anti-mouse 
Millipore (Cat 
No: AB769) 
Table 3-3: Antibodies for intravascular injection 
Analysis Marker Fluorochrome Clone Company 
Epithelial 
cells 
cytokeratin 8 N/A 
Purified Ab 
N/A 
Polyclonal 
rabbit anti-
mouse 
Novus 
Biologicals 
 cytokeratin 18 N/A 
Purified Ab 
N/A 
Polyclonal 
rabbit anti-
mouse 
Novus 
Biologicals 
HEV PNAd N/A 
Purified Ab 
MECA-7 
Rat anti-
mouse 
BD 
Biosciences 
Vascular 
Endothelium 
CD31 AF488 MEC13.3 BioLegend 
 CD31 AF647 MEC13.3 BioLegend 
T cells CD4 AF700 RM4-5 eBioscience 
 CD4 AF647 RM4-5 BioLegend 
 CD8α PE-Cy7 53-6.7 eBioscience 
 CD8β AF647 YTS156.7.7 BioLegend 
 CD44 APC-eF780 IM7 eBioscience 
 CD45.2 BV650 104 BioLegend 
 CD62L PerCP-Cy5.5 MEL-14 BioLegend 
 CD69 eF450 H1.2F3 eBioscience 
 CD90.1 
(Thy1.1) 
eF450 HIS51 eBioscience 
 CD90.1 
(Thy1.1) 
AF647 OX-7 BioLegend 
 CD103 APC 2E7 eBioscience 
B cells 
CD11c APC-eF780 N418 eBioscience 
 CD19 AF700 eBio1D3 eBioscience 
 CD38 PE-Cy7 90 BioLegend 
 CD45.2 BV650 104 BioLegend 
 CD90.2 
(Thy1.2) 
APC-eF780 53-2.1 eBioscience 
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 B220 V500 RA3-6B2 BD 
Biosciences 
 F4/80 APC-AF750 REF: 
MF48027 
Invitrogen 
 GL7 eF450 GL-7 eBioscience 
 Ig (H+L) AF350 Cat: A11068 Invitrogen 
 IgD PerCP-Cy5.5 11-26c.2a BioLegend 
 IgM APC II/41 eBioscience 
 Ly6G APC-eF780 RB6-8C5 eBioscience 
Myeloid cells CD11b APC-eF780 M1/70 eBioscience 
 CD11c PE-Cy7 N418 eBioscience 
 CD45.2 BV650 104 BioLegend 
 CD68 PerCP-Cy5.5 FA-11 BioLegend 
 CD103 APC 2E7 eBioscience 
 Ly6C FITC AL-21 BD 
Biosciences 
 Ly6G AF700 IA8 BioLegend 
 MHC II I-Ab eF450 M5/114.15.2 eBioscience 
IHC Goat anti-
Rabbit 
AF488 N/A Invitrogen 
 Goat anti-
Rabbit 
AF555 N/A Invitrogen 
 Donkey anti-
Goat 
AF488 N/A Invitrogen 
 Donkey anti-
Goat 
AF555 N/A Invitrogen 
 Donkey anti-
Rat 
AF488 N/A Invitrogen 
 Donkey anti-
Rabbit 
AF647 N/A Jackson 
Immuno 
Research 
Laboratories 
Table 3-4: Antibodies for ex vivo staining for flow cytometry or 
immunofluorescence 
 
Immunofluorescence Microscopy 
Immunofluorescence staining was performed as described (123, 126, 155). 
Briefly, tissues were frozen in O.C.T. on dry ice. 7µm frozen sections were cut 
using a Leica cryostat. Slides were fixed in cold acetone for 10 minutes. Prior to 
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staining, slides were rehydrated for 10 minutes in PBS. All slides were blocked 
for 60-90 minutes with 5% bovine serum albumin (BSA) in PBS. Secondary 
antibodies were used for 30 minutes at room temperature. DAPI staining was 
performed for 10 minutes. Cover slips were mounted with Prolong Gold Anti-
Fade mounting reagent (Invitrogen). A Leica DM5500B epifluorescent 
microscope with Leica Acquisition Suite Advanced Fluorescence software was 
used for image acquisition. Adobe Photoshop was used for image analysis. 
Confocal Microscopy 
55µm frozen sections were cut using a Leica cryostat. A Leica SP5 laser 
scanning confocal microscope with Leica acquisition suite software was used for 
image acquisition. Imaris 7.6 (bitplane) software was used for image analysis. 
Statistical Analysis 
All statistical comparisons were performed using Prism 5 software (Graphpad). 
Analyses utilized a two-tailed unpaired t-test with 95% confidence intervals. All 
error bars represent standard error of the mean (SEM).  
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Chapter 4 
 
The role of memory T cells during anamnestic 
responses to respiratory challenge 
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Myriad factors influence how leukocytes contribute to disease processes. 
While cell differentiation state accounts for some mechanistic differences 
between cell lineages, factors dependent on the physical location of the cell, 
such as the milieu of the tissue microenvironment, proximity to the site of 
infection, and physical barriers preventing cell-to-cell contact, also play a major 
role in immune responses to disease. In the lung, numerous leukocyte-containing 
tissue and blood compartments exist, and cells within these different 
microenvironments may play distinct roles during anamnestic responses to 
infection. Here we use intratracheal cell transfer and parabiotic methods along 
with intravascular staining to study the contributions of memory T cells within the 
airways or the tissue of the lung to secondary challenge. We demonstrate that 
the milieu of the lung airways significantly alters cell surface phenotype of 
memory T cells and inhibits division of T cells programmed to undergo 
proliferation. We also confirm the presence of a resident memory T cell 
population in the lung tissue. Finally, we show evidence that memory T cells 
within the lung tissue prior to secondary challenge are involved in recall of 
additional antigen-specific memory T cells to the site of infection. These findings 
have significant implications for the development of vaccines aimed at 
developing local T cell memory against respiratory infections.    
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Introduction 
Leukocytes are found within numerous compartments of the respiratory tract: 
airspace, large blood vessels, alveolar capillaries, bronchiolar epithelium, 
inducible bronchus associated lymphoid tissue (iBALT), alveolar aggregates, 
pericapillary, and lamina propria. Cells in each of these locations are exposed to 
a different milieu of cytokines, such as TGF-β, and barrier surface conditions, 
such as surfactants and lung microbiota. Tissue milieu has been shown to affect 
leukocyte differentiation, proliferative capacity, and recruitment in numerous 
organs (114, 143, 155, 306) including the lung (123, 126, 290). Further, it has 
been suggested that a paucity of direct cell-cell contact likely impacts the 
response time of cells during pathogen encounter (291, 307). As cells in the lung 
vasculature are likely prevented from making cell-to-cell contacts with infected 
cells in the lung tissue or airways by endothelial cells and the underlying collagen 
matrix, cells in these distinct compartments of the lung may contribute differently 
during anamnestic responses.   
 Adoptive transfer of T cells expressing a traceable congenic marker, such 
as CD45.1/2 (Ly5.1/2) or CD90.1/2 (Thy1.1/2), or cells labeled with a detectable 
dye, such as carboxyfluorescin succinimidyl ester (CFSE) or cell tracker violet, 
into recipient mice can be used to study the role of distinct cell types during a 
memory response. Importantly, the route of cell transfer can also be utilized to 
focus on the role of cells in unique tissue locations. For instance, intratracheal 
(i.t.) transfer, followed by bronchioalveolar lavage (BAL), can be used to study 
the effects of the airway microenvironment on T cells and the role of these cells 
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in a response to airway challenge (238, 254). On the other hand, intravenous 
(i.v.) transfer of a population of interest may be used to monitor migration, 
differentiation, and effector functions of cells circulating through secondary 
lymphoid organs and vasculature. While the presence of T cells within the lung 
airways correlates with protection against secondary challenge (238, 301), and 
these have been shown to wane together over time (168, 169, 307), further 
studies are needed to fully characterize the contribution of airway T cells during 
immune responses to respiratory infections.  
 Airway memory T cells wane over time; however, memory T cells can be 
isolated from the lung many months after clearance of an infection, suggesting T 
cells within different compartments of the lung may have different retention 
capacities. Resident memory T cells (TRM), a subset of effector memory T cell 
(TEM), have been shown to be long-lived and play a role in both the recruitment of 
additional memory T cells as well as protection against local challenge within 
non-lymphoid tissues (122-124, 155, 169, 292). One of the most definitive 
methods for defining TRM is through the use of parabiotic experiments. In these 
systems, two congenically distinct partners are surgically conjoined for 2-4 
weeks, allowing the circulatory systems of the partners to anastomose, or fuse. 
Cells originating from either parabiont partner can then be tracked for migration 
to the conjoined partner or retention within the original host. Use of parabiosis in 
combination with intravascular staining (126, 254, 293) allows for the 
characterization of intracellular and cell surface marker expression specific to 
TRM. 
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One major regulator of T cell trafficking is the transcription factor Kruppel-
like factor 2 (KLF2). In addition to directly regulating the expression of L-selectin 
(CD62L) and sphingosine 1 phosphate receptor 1 (S1PR1) (238, 294), receptors 
that are required for lymph node entry and egress, respectively, KLF2 represses 
chemokine receptor expression (138, 155, 254, 295). All of these molecules play 
distinct, yet critical roles in lymphocyte migration. In fact, reduced expression of 
KLF2 within CD8 T cells in non-lymphoid tissues results in the establishment of 
TRM in the kidney, small intestine epithelium, salivary gland, and brain (126, 155, 
254). While this mechanism ok KLF2 down-regulation is involved in the 
establishment of TRM in several non-lymphoid tissues, investigation of this 
process in the lung to date is lacking.    
Here we explore the contribution of memory CD8 T cells in the airspace 
and tissue of the lung to antigen-specific or antigen-irrelevant secondary 
responses. We demonstrate that environmental factors within the airway 
modulate the expression of cell surface molecules and inhibit T cell proliferation, 
and we utilize parabiosis in conjunction with intravascular staining to demonstrate 
the presence of a CD8 TRM population within the lung tissue. Together, these 
data provide evidence that distinct populations of memory T cells exist within the 
lung. 
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Results 
Intratracheal transfer of memory splenocytes alters cell surface phenotype 
T cell memory within the lung airways wanes over time (168, 169, 238). To 
bypass the complications of low cell recoveries in endogenous systems, we 
adoptively transferred memory P14 splenocytes (>30 days after primary 
infection) intratracheally (i.t.) to study the behavior of airway cells (119, 180, 
254). P14 T cells are transgenic CD8 T cells that express a T cell receptor (TCR) 
specific for the gp33-41 epitope of lymphocytic choriomeningitis virus (LCMV). 
Within 24 hours of transfer, donor P14 T cells displayed modest changes in the 
expression of cell surface molecules, consistent with previously published 
findings. For example, i.t. transfer of memory T cells primed with Sendai virus 
infection have reduced expression of the αL integrin component of lymphocyte 
function-associated antigen 1 (LFA-1), also referred to as CD11a (126, 180). We 
observed this same reduction in CD11a expression on memory T cells generated 
by LCMV infection and transferred into the airway of naïve mice (Figure 4-1). We 
also observed reduced expression of the tumor necrosis family (TNF) receptor 
CD27 and the interleukin 7 receptor-α (IL-7Rα) chain (CD127), consistent with 
observations by Woodland and colleagues (107-109, 111, 180). Importantly, this 
change begins to occur within 24 hours of transfer, but the reduction is most 
significant after greater duration in the airspace (Figure 4-1). As previously 
reported, expression of CD69, a marker correlated with antigen experience or 
residency, remained stable. However, expression of CD44, another marker 
99 
correlated with antigen experience and memory, was slightly reduced (Figure 4-
1). Together, these findings are consistent with the hypothesis that the airway 
environment influences T cell phenotype.   
 
Figure 4-1: Intratracheal transfer of memory splenocytes alters cell surface 
phenotype. Memory P14 splenocytes were transferred i.t. into naïve C57Bl/6 
recipients. 24 (a) or 72 (b) hours later, cells were isolated from the airway by 
bronchioalveolar lavage and assessed using flow cytometry for cell surface 
expression of CD11a, CD27, CD127, CD69, and CD44. Plots are representative 
of 3 mice per condition from 1 experiment. 
 
T cell proliferation is inhibited within the lung airspace  
To explore the effects of the airway environment on T cell proliferation, we 
treated memory P14 T cells with carboxyfluorescin succinimidyl ester (CFSE), 
initiated proliferation in vitro, and adoptively transferred the cells using either an 
intratracheal (i.t.) or intravenously (i.v.) route. CFSE is a green fluorescent dye 
commonly used to track cell proliferation (108-110, 296-300). CFSE forms 
covalent bonds to amine groups within intracellular proteins; during cell division, 
the dye is dispersed in equal proportions to newly formed daughter cells. 
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Consequently, dilution of the dye within a population of cells results in a reduction 
of fluorescence intensity, indicative of the number of rounds of division the cells 
have experienced.   
 P14 T cells cultured in vitro with gp33-coated splenocytes begin to dilute 
CFSE as early as 24 hours (Figure 4-2A). By 48 hours in culture, the cells have 
undergone several rounds of division, and by 96 hours in culture, some P14 T 
cells have completely diluted CFSE, indicating they have undergone at least 6 
rounds of division (Figure 4-2A). P14 T cells cultured with splenocytes lacking 
gp33 peptide remain CFSE high during the duration of in vitro culture. To assess 
the proliferation of P14 T cells in vivo, CFSE-coated P14s were stimulated in vitro 
for 24 or 48 hours and transferred i.v. via the tail vein. P14 splenocytes 
transferred i.v. continued to proliferate, and had fully diluted CFSE 1-2d after 
transfer (96 hours from initial stimulation). However, cells stimulated under the 
same conditions and transferred i.t. ceased CFSE dilution. Notably, when cells 
were transferred after 48 hours in culture, after several rounds of proliferation 
occurred and CFSE fluorescence intensity had been reduced, cells transferred 
i.t. failed to further dilute CFSE, indicating an arrest in cell division (Figure 4-2B).   
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Figure 4-2: T cell proliferation is inhibited in the airways. (a) P14 splenocytes 
were treated with CFSE and stimulated in vitro using gp33-peptide-coated 
congenic splenocytes (peptide) or media alone (no stim). (b) After 24 or 48 
hours, stimulated P14 splenocytes were transferred either i.v. or i.t. into naïve 
recipients. Cells were isolated from the spleen or airways 96 hours after initial 
stimulation and assessed for CFSE dilution using flow cytometry. Plots are 
representative of 6 recipient mice per condition from 2 independent experiments. 
N.D. = not detectable.  
 
We noted that we were also able to isolate P14 T cells that had fully 
diluted CFSE from the airways of mice that received an i.v. transfer of donor 
cells. To examine whether these cells migrated to the airway and continued 
proliferation in the airways or completed proliferation prior to entry of the airway, 
we prepared P14 memory T cells with CFSE labeling and in vitro stimulation, as 
before, but we also treated the cells with media or pertussis toxin (PTx) prior to 
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i.t. transfer. Naïve P14 splenocytes were coated in CFSE prior to i.t. transfer as a 
negative control for CFSE dilution. Four days after transfer, only CFSE high cells 
could be isolated from the airways (Figure 4-3A, top row). However, very low 
numbers of donor memory P14 T cells (but not naïve P14 donor cells) treated 
with media could be recovered from spleen and mediastinal LN and displayed 
dilution of CFSE at both time points examined (Figure 4-3B and data not shown). 
Notably, naïve cells and P14 donor cells treated with PTx were not detected in 
any secondary lymphoid organs at any time point assessed (data not shown). By 
7 days after transfer, memory cells treated with media alone could be isolated 
from the airways, and a fraction of these cells had completely diluted CFSE 
(Figure 4-3A, bottom row, center panel). However, only CFSE-high donor cells 
could be recovered from the airways of mice that received PTx-treated donor 
cells (Figure 4-3A, bottom row, right panel). These data suggest that memory T 
cell proliferation is indeed inhibited within the lung airways. Further, these data 
also support the hypothesis that chemokine signaling allows T cells to exit the 
airways and return to secondary lymphoid organs. 
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Figure 4-3: T cell proliferation occurs outside of lung airways. Memory P14 
splenocytes were coated with CFSE and stimulated in vitro using gp33-peptide-
coated splenocytes. Cells were treated with media (no PTx) or pertussis toxin (+ 
PTx) prior to i.t. transfer. Unstimulated naïve P14 T cells were transferred as a 
negative control for CFSE dilution. Cells were isolated from the (a) airway by 
lavage or (b) mediastinal lymph node or spleen 4 or 7 days after transfer and 
assessed for CFSE dilution by flow cytometry. Transferred Thy1.1 cells were not 
detectable in the mediastinal LNs or spleens of mice receiving naïve P14s of 
memory P14s treated with PTx. Plots are representative of 2 (Naïve and +PTx) 
or 3 (-PTx) mice per condition from 1-2 independent experiments.   
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In vivo peptide administration within lung airways results in cell loss  
One mechanism by which CD8 T cells contribute to pathogen control is 
through secretion of cytokines such as interferon-γ (IFN-γ) and tumor necrosis 
factor-α (TNF-α). Since the cell surface phenotype and proliferative capacity of 
memory T cells in the airways is altered, we wished to assess the ability of 
memory T cells within the airways to secrete cytokines after re-stimulation in 
vivo. To this end, P14 memory splenocytes were transferred i.t. into naïve 
recipients. One day later, mice received an i.t. administration of media or gp33 
peptide, and 2 hours later airway cells were isolated via BAL. Cells recovered 
from the airway were incubated in vitro with media or gp33 peptide and Golgi 
Plug (Golgi Plug is a chemical inhibitor of protein transport, which results in 
protein accumulation within the Golgi complex of the cell. This allows for 
detection of cytokine production using intracellular staining and flow cytometry). 
Donor P14 splenocytes were also stimulated with media or peptide in vitro as 
negative and positive controls, respectively. As expected, cells receiving no 
peptide stimulation produced neither cytokine (Figure 4-4, top left and bottom left 
panels), while cells receiving in vitro peptide stimulation readily produced both 
cytokines (Figure 4-4, right column). We observed cells within the airways that 
only received in vivo peptide stimulation were also able to produce both 
cytokines (Figure 4-4, left column, middle panel), although at a reduced 
frequency compared to those only stimulated in vitro. 
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Figure 4-4: Splenocytes within lung airways secrete cytokines in response 
to peptide. 5 x 106 memory P14 donor splenocytes were transferred i.t. 1 day 
prior to peptide challenge. Recipient mice received media (top row) or gp33 
peptide (middle row) i.t. 2 hours later, cells were recovered from airways via 
lavage and incubated in vitro with media (left column) or gp33 peptide (right 
column) for an additional 3 hours. Plots display concatamerized data from all 
mice (n = 3 per condition for BAL samples, n = 1 donor spleen) from 1 
experiment. Percentages represent the average of all mice in each condition. 
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We also noted that the number of recoverable cells from BAL was 
significantly reduced in animals that received an i.t. administration of peptide. 
CD8 T cell fratricide has been reported under conditions of cognate ligand 
expression using in vitro model systems (247, 301-304) and in vivo infectious 
systems (148, 304, 305). While T cell fratricide may explain these findings, it is 
also possible that in vivo stimulation with peptide results in rapid egress of 
antigen-specific T cells from the airway to secondary lymphoid tissue. Thus, we 
wished to determine if the reduced cell recovery was due to cell death upon 
peptide encounter or cell egress from the airway. To investigate this observation 
further, we transferred an equal number of CFSE-labeled memory P14 
splenocytes i.t. into naïve mice and challenged one day later with either gp33 
peptide or a recombinant form of Listeria monocytogenes expressing gp33 (LM-
gp33).  
Two hours or three days after challenge, CFSE high donor cells could be 
recovered from animals administered either challenge (Figure 4-5A, left and 
middle panels), but the number of recovered cells from the peptide challenged 
animals were markedly lower than the animals receiving the infection. By 8 days 
after challenge, CFSE-diluted donor cells could only be recovered from the 
airways of mice challenged with LM-gp33 (Figure 4-5A, right panels). In addition, 
donor cells could only be recovered from spleens of mice challenged with LM-
gp33 (Figure 4-5B), and these cells had completely diluted CFSE by 8 days after 
infection (Figure 4-5C). Together, these data are consistent with the hypothesis 
that CD8 T cells in the airways exposed to peptide stimulation are undergoing 
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cell death rather than migration out of the airways. However, we cannot rule out 
the possibility that infection with a pathogen provides survival factors and/or 
migration cues that are absent during challenge with peptide alone. Further 
experiments are required to fully interpret these results.   
 
Figure 4-5: In vivo peptide administration results in P14 cell loss. Memory 
P14 splenocytes were coated with CFSE and transferred i.t. 1 day prior to 
challenge with gp33 peptide or LM-gp33. P14 donor cells were recovered from 
the airways via BAL (a) or the spleen (b&c) and assessed for CFSE dilution 2 
hours, and 3 or 8 days after challenge. Plots in (a) display concatamerized data 
of all mice (n = 3 per condition) from 1 experiment. (b&c) Representative plots 
from 3-5 mice per condition in 1-2 independent experiments.  
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Lung tissue contains both non-recirculating TRM and circulating TEM 
Reduction in the expression of the transcription factor KLF2 has been shown to 
result in the formation of TRM populations within non-lymphoid tissues (126, 308). 
To determine whether TRM cells reside in the lung tissue, we generated 
congenically distinct P14 immune chimeric mice. After >30 days, infection-
matched memory mice were conjoined through parabiosis to allow shared 
circulation to develop (Figure 4-6A). Three weeks after surgery, approximately 
equal ratios of P14 T cells from each animal could be found in the peripheral 
blood circulation (data not shown). To assess the presence of resident or 
circulating donor memory cells in tissues, we injected anti-CD8β Ab i.v., 
sacrificed the animals, and harvested lymphoid and non-lymphoid tissues to 
examine KLF2 expression in P14 T cells derived from either donor.   
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Figure 4-6: Lung tissue contains non-recirculating TRM. Congenically distinct 
P14 memory mice were generated by transferring either naïve P14 T cells 
expressing a KLF2-GFP fusion protein (CD45.1/2) or naïve wild type (WT) P14s 
T cells (CD45.1) into naïve C57Bl/6 recipients (CD45.2) and infecting with LCMV 
i.p. 1 day later. >30d after infection, hosts containing distinct memory T cell 
populations were surgically conjoined. (a) Parabiosis schematic. (b) Four weeks 
later, intravascular staining was used to quantitate the proportion of recirculating 
memory cells in spleen (SPL), lymph node (LN), peripheral blood (PBL), small 
intestine epithelium (SI IEL), salivary gland (SG), female reproductive tract 
(FRT), liver, (Liv), and lung tissues. Results are presented as the frequency of 
P14 T cells among total CD8+ cells in the parabiont divided by the counterpart in 
the donor. Data are representative of 6 parabiont pairs (12 mice total) from 2 
independent experiments. Error bars = SEM.  
 
 
  As expected, approximately equal proportions of P14-GFP to P14-WT 
cells could be found in the spleen, lymph nodes and peripheral blood of the WT 
memory animal after 4 weeks (Figure 4-6B). However, consistent with previously 
published results, P14-GFP memory cells failed to enter the small intestine 
epithelium (SI IEL), salivary gland (SG) and female reproductive tract (FRT) of 
the WT animal (123, 126, 309) (Figure 4-6B), confirming that memory cells within 
these tissues are non-recirculating TRM. Non-lymphoid tissues such as the liver 
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and lung, however, neither completely equilibrated (like the lymph nodes), nor 
remained completely resident (such as the SI IEL, SG, and FRT), suggesting that 
these tissues may contain both populations of memory T cells: non-circulating 
TRM and recirculating TEM (Figure 4-6B).  
 KLF2 regulates the expression of the T cell migration markers CD62L and 
S1PR1 (177, 294); consequently, a reduction in KLF2 expression correlates with 
a reduction in sensitivity to S1P signaling in the blood and lymph, resulting in 
cells that are refractory to egress signals. S1PR1 expression also inversely 
correlates with expression of CD69 (126, 251). Consequently, KLF2 reduction 
and/or CD69 expression are used as surrogate markers for TRM. To examine the 
expression of KLF2 and CD69 on resident and recirculating cells in the lung, we 
compared KFL2-GFP and CD69 expression levels from P14-GFP memory cells 
within the donor and parabiont partner. As expected, the lymph nodes of P14-
GFP and P14-WT memory mice contained equivalent populations of KLF2hi 
CD69lo memory P14 cells from the donor P14-GFP mouse (Figure 4-7A, second 
row), confirming that the lymph node compartment contains recirculating memory 
cells. The SG and FRT of the P14-GFP donor mouse both contained KLF2lo 
CD69hi TRM populations, which were lacking in the P14-WT mouse (Figure 4-7A), 
consistent with previously published reports of T cell residency within these 
tissues (122, 123, 126, 228). Furthermore, the splenic white pulp of the P14-GFP 
donor mouse contained a sizeable fraction of KLF2lo CD69hi TRM, consistent with 
recent findings regarding the presence of TRM within lymphoid tissues (156).  
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Figure 4-7: TRM in the lung reduce expression of KLF2. Congenically distinct 
P14 memory mice were generated by transferring either naïve P14 T cells 
expressing a KLF2-GFP fusion protein (CD45.1/2) or naïve wild type (WT) P14s 
T cells (CD45.1) into naïve C57Bl/6 recipients (CD45.2) and infecting with LCMV 
i.p. 1 day later. >30d after infection, hosts containing distinct memory T cell 
populations were surgically conjoined. Four weeks later, intravascular staining 
was used to distinguish cells within tissue (a) and blood (b) compartments of the 
indicated tissues. Plots are concatamerized data from 3 mice per condition and 
are representative of 6 parabiont pairs (12 mice) from 2 independent 
experiments. 
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Notably, KLF2lo CD69hi TRM populations were identified within the liver and 
lung tissue compartments of the P14-GFP donor mice (Figure 4-7A), although 
these populations constituted only 68% and 32% of the memory cells in the 
tissue, respectively (compared to P14-WT mice, which contained 17.3% and 
9.4% in liver and lung, respectively). This further supports the interpretation that 
the liver and lung contain both non-recirculating TRM and circulating TEM 
populations. Interestingly, we observed that the P14-WT recipient liver tissue 
also contained a fraction of KLF2lo CD69hi TRM derived from the parabiont partner 
(Figure 4-7A). While it is possible that some tissue compartments are accessible 
to circulating memory T cells and may be seeded with new TRM, an alternative 
explanation is that additional S1P receptors, such as the other S1PR family 
members S1PR2, S1PR3, S1PR4, and S1PR5 (124, 306), also play a role in T 
cell recirculation. Regardless of the mechanism, this finding is consistent with the 
notion that CD69 is an imperfect marker of TRM (123, 126). Finally, we noted that 
three compartments accessible by intravascular Ab, the peripheral blood, liver 
sinusoids and lung vasculature, also contained small populations of KLF2lo 
CD69hi TRM (Figure 4-7B, left panels). Although resident populations of 
leukocytes in vascular compartments have previously been reported (251, 307), 
we cannot rule out the possibility that additional S1P receptors also play a role in 
T cell recirculation. Further experiments are needed to fully understand the 
implications of these data.  
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Memory CD8 T cells are rapidly recalled to the lung tissue after local 
antigen challenge  
Local antigen-specific memory CD8 T cells can secrete cytokines, elicit 
cytotoxic functions, and induce rapid recall of additional memory T cells upon 
exposure to antigen. We wished to asses whether the presence of antigen-
specific memory T cells within the lung tissue would also be associated with rapid 
recall responses after a local lung challenge. To this end, we generated P14 
memory mice containing memory T cells in the lung tissue via intratracheal (i.t.) 
infection with LCMV as previously described (160, 254). After 140 days, mice 
were re-challenged i.t. with media (ø), irrelevant peptide (AL11, a peptide from 
the gag protein of simian immunodeficiency virus), LCMV-derived peptide (gp33), 
recombinant Vaccinia virus expressing an irrelevant antigen (VV-gag), or 
recombinant Vaccinia virus expressing an LCMV-specific antigen (VV-gp33). At 
12, 24 and 48 hours after challenge, intravascular staining was performed and 
the lungs of mice were frozen for histological analysis.   
  No quantitative difference was observed between any groups by 12 hours 
after challenge (Figure 4-8A). However, by 24 hours, the lungs of mice 
challenged with Vaccinia containing a relevant P14 T cell epitope contained 
significantly more P14 T cells than unchallenged animals (Figure 4-8B). Notably, 
mice challenged with gp33 peptide also appear to have more cells than 
unchallenged animals; however, this difference is not statistically significant. We 
hypothesize, based on the previous peptide challenge experiments (Figure 4-4 
and Figure 4-5), that the results observed in the animals challenged with peptide 
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alone may be a reflection of concurrent cell recall and cell death, although 
additional experiments are needed to thoroughly test this hypothesis.  
 By 48 hours after challenge, we observed a significant increase in P14 T 
cells within mice challenged with relevant antigen, regardless of form during 
administration. Notably, a small increase in P14 T cells was observed in animals 
challenged with an infection containing irrelevant antigen as well (Figure 4-8C). 
While this increase was not statistically significant over unchallenged controls, it 
is also not significantly different from the animals challenged with relevant 
antigen. Further experiments are needed to determine if irrelevant infection can 
also induce a minor recall response within the lung tissue. Future experiments 
examining the recall of other immune cell types will also significantly contribute to 
our understanding of the role of memory CD8 T cells during secondary 
responses to infection.  
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Figure 4-8: Rapid recall of antigen-specific memory T cells to lung tissue 
after local challenge with antigen. After 140 days, we re-challenged the mice 
i.t. with media (ø), irrelevant peptide (AL11, a peptide from the gag protein of 
simian immunodeficiency virus), relevant peptide (gp33), recombinant Vaccinia 
virus expressing an irrelevant antigen (VV-gag), or recombinant Vaccinia virus 
expressing a relevant antigen (VV-gp33). At 12 (a), 24 (b) and 48 (c) hours after 
challenge, intravascular staining was performed and the lungs of mice were 
frozen for histological analysis. Data are representative of 4-5 mice per condition 
from 2 independent experiments. * p<0.05, ** p<0.01, n.s. = not significant. Error 
bars indicate SEM.  
 
Discussion 
Within the lower respiratory tract, the pulmonary-alveolar barrier between 
airspace and vasculature consists of two cells, an endothelial cell and an alveolar 
epithelial cell, with a fused basal lamina. Hence, this interface constitutes a 
delicate barrier surface exposed to the external environment. Pulmonary alveolar 
epithelial cells are constantly exposed to environmental antigens, both innocuous 
and pathogenic. Consequently, a careful balance must be maintained between 
immune responses poised to contain infection and regulation of responses to 
minimize tissue pathology. Much like the dual-functionality that alveolar epithelial 
cells provide in both efficient gas exchange and as a barrier surface, other 
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factors unique to the lung environment, such as surfactant proteins, also play 
multiple roles in homeostatic maintenance. For instance, surfactant protein A 
(SP-A) reduces surface tension at the alveolar air-liquid interface, but SP-A also 
has an immunomodulatory role. SP-A serves as a scavenger receptor and 
opsonin (124, 310-314) promoting innate immune responses, but SP-A also 
suppresses T cell proliferation (119, 121, 122, 155, 290, 315-317) and IL-2 
secretion (155, 158, 159, 318). Our findings regarding modulation of memory T 
cell phenotype, proliferation, and cytokine secretion are consistent with 
previously published results, although further work is needed to elucidate 
whether SP-A or an alternate mechanism is responsible for the phenotypic 
modulation and cytokine suppression we observed. 
 Previous studies have suggested that the cells arriving in the lung airways 
were in a state of terminal differentiation (169, 180, 311, 319, 320), and 
speculated that these cells would eventually be expelled from the body, likely via 
the mucociliary escalator. Therefore, in our experiments involving i.t. transfer of 
memory cells, it was surprising to see memory cells retained the ability to egress 
and return to secondary lymphoid tissue. It could be argued that these 
observations are an artifact derived from the adoptive transfer system utilizing a 
large number of transgenic splenocytes, as the expression of migratory 
molecules, differentiation state, proliferative potential, and function of splenocytes 
and cells within the airway are notably different (168, 169, 180). However, in all 
experiments, the donor cells were parked in the airways at least 24 hours prior to 
challenge, which is enough time to allow the cells to modulate expression of cell 
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surface markers characteristics of splenocytes to resemble airway T cells (Figure 
4-1). Thus, it is interesting to speculate that memory T cells migrating into the 
airways may not be on a “one-way trip”. Additional experiments involving the 
transfer of labeled airway cells may shed some light on the physiological 
relevance of this phenomenon.  
 Additionally, while cells in the airways have previously been described as 
a population of effector T cells poised to protect against infection at the 
respiratory interface, the experiments in which challenge with peptide resulted in 
cell loss may allude to another role for these cells. T cells engaged in the process 
of fratricide have been shown to express IFN-γ and TNF-α (237, 301), consistent 
with our observations (Figure 4-4), yet they also mediate cytotoxic effects against 
other CD8 T cells via perforin-mediated mechanisms. Consequently, it is possible 
that cells within the airways also play a regulatory role during immune responses 
in the respiratory tract. Further investigation is needed to determine if memory T 
cells in the airways also play an immune-regulatory role in the lungs.   
 In light of the protective role TRM have been shown to play, efforts to 
improve the generation of TRM in the lung tissue may be critical for the 
development of T cell vaccines against respiratory pathogens, such as influenza 
and Mycobacterium tuberculosis. We have shown that a population of TRM does 
exist in the lung tissue, but that not all memory cells in the lung are resident. The 
factors that make this tissue distinct from non-lymphoid tissues containing 
predominantly TRM memory, such as the small intestine epithelium and female 
reproductive tract (which are also a barrier surfaces), remain to be elucidated. 
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Teleologically, perhaps the lung only contains a fraction of TRM to preserve 
optimal gas exchange function. Alternatively, perhaps some cells lacking CD69 
expression are also resident and are retained in the tissue by alternate 
mechanisms. Yet another explanation for these findings may be that local lung 
infection generates a more substantial population of lung-localized TRM. These 
unresolved questions merit further investigation.    
 Although resident leukocyte populations have been described within 
vascular compartments previously (307, 321), we were surprised to find such a 
large population of KLF2lo CD69hi T cells within the peripheral blood. Since the 
peripheral blood leukocytes in the parabiosis experiments were obtained via 
cardiac puncture, we cannot rule out the possibility that the isolated cells had 
recently re-entered the vascular circulation through the thoracic duct. For 
instance, if memory cells managed to egress from non-lymphoid tissue but 
lacked expression of the major lymph node homing molecule CCR7, they would 
likely travel through the sinuses of lymph nodes, back to the venous circulation, 
into the right atria and ventricle of the heart, and out to the pulmonary 
vasculature. This alternative scenario could explain the presence of TRM 
phenotype cells within the vascular compartments of the peripheral blood, lung 
and liver of the parabiont partners. Further experiments are needed to determine 
the origin of these cells, as well as to refine the markers used to characterize true 
TRM.   
 Fully elucidating the role of tissue localized memory T cells during a 
second exposure to antigen is an active area of interest. Our findings suggest 
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that local memory CD8 T cells may be involved in recall responses; however, the 
kinetics of the responses to different pathogens may vary significantly. For 
example, others have demonstrated that heterosubtypic responses to influenza 
virus do not result in accumulation of antigen-specific memory T cells until ~5 
days after challenge (169). Thus, the kinetics of the memory T cell response may 
be heavily influenced by the agent used for secondary challenge. As these 
issues are all relevant for the development of efficacious vaccines, future work 
will need to address these unresolved questions. 
 
Materials and Methods 
Mice and infections 
C57Bl/6 and CD45.1 congenic B6 mice were purchased from Jackson 
Laboratories or the National Cancer Institute and used at 6-8 weeks of age. P14 
TCR transgenic mice expressing the H-2Db restricted LCMV gp33-41 epitope 
[KAVYNFATC] expressing Thy1.1 or CD45.1/2 were used for the described 
studies. P14 chimeric immune mice were generated as described (155, 170, 
322). CD45.1 P14 were crossed to KLF2GFP reporter mice for parabiosis studies 
(126, 162, 323-328). Mice were either infected intraperitoneally (i.p.) with 2 x 105 
PFU LCMV or intratracheally (i.t.) with 1 x 105 PFU LCMV (238). Mice challenged 
with pathogens received 5 x 103 cfu LM-gp33, 5 x 105 pfu VV-gp33, 5 x 105 pfu 
VV-OVA, or 5 x 105 pfu VV-SIV-gag i.t.. Mice challenged with peptide received 
1µg/ml of gp33, SIINFEKL, or AL11 peptide in 100µl volume i.t. Animals were 
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maintained under specific pathogen-free conditions at the University of 
Minnesota, and the IACUC approved all experiments. 
Intravascular staining and cell isolations 
3 µg of Anti-CD8α-APC, anti-CD8α-PE, or purified anti-CD8α (clone: 53-6.7 from 
eBioscience) or anti-CD8β Pacific Blue (clone: 53-5.8 from Biolegend), were 
injected intravenously (i.v.). Three minutes later, the animals were sacrificed, 
lavaged to remove cells in the airway, bled, and perfused with 10 ml of cold 
phosphate buffered saline (PBS). The peripheral blood, spleen, LNs, lung, liver, 
kidney, brain, female reproductive tract, and small intestine were harvested 
within 12min, and lymphocytes were isolated as described (138, 155, 254). 
Spleen, lymph nodes and livers were homogenized through 70µm filter in RPMI 
1640 containing 5% FBS. All tissue pieces were washed several times with 5% 
RPMI 1640 medium to remove excess of injected antibody prior to enzymatic 
digestion. Lung was removed, dissected into small pieces and the pieces were 
incubated with 1.3 mM EDTA in HBSS (30 min at 37°C, 400 rpm) followed by 
treatment with 100 U/ml Type I collagenase in 5% RPMI 1640 medium/2 mM 
MgCl2/2 mM CaCl2 (45 min/37°C, 400 rpm). For isolation of intraepithelial 
lymphocytes (IELs) from small and large intestine the organs were removed, 
fecal contents were removed, Peyer’s Patches were excised (from small intestine 
only), the intestines were cut longitudinally and then into 1cm pieces.  They were 
incubated in 10% 1xHBSS/Hepes Bicarbonate containing 15.4mg/100ml 
dithioerythritol (30 min at 37°C, 400 rpm) to extract IEL. After separating IELs, 
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the gut pieces were further treated with 100U/ml Type I Collagenase 
(Worthington) for lamina propria lymphocyte (LPL) isolation. Kidneys and female 
reproductive tract (containing uterine horns, cervix, and vaginal tissue) were 
removed and cut into small pieces followed by treatment with 100U/ml Type I 
(Worthington) and type IV (Sigma) Collagenase respectively in 5% RPMI 
1640/2mM MgCl2/2mM CaCl2 (45 min at 37°C, 400rpm). The lymphocytes from 
liver, lung, gut, kidney and FRT were purified on a 44/67% Percoll gradient 
(800xg at 23°C for 20 min). Immunofluorescence staining was performed as 
described (155, 254). 
Intratracheal cell transfers 
Splenocytes from memory P14 immune chimeras were collected >30d after 
LCMV infection. Donor cells were washed and resuspended in RPMI 1640. 
Naïve C57Bl/6 recipient mice were anesthetized with 0.4-0.75 mg/g 2-2-2-
tribromoethanol (Avertin, Sigma Aldrich) in accordance with IACUC guidelines 
and 100 µl (5 x 106 cells) of the cell suspension were instilled into the lungs via a 
1-ml syringe fitted with a 25-G needle (238).  
CFSE Treatment 
Purified splenocytes from P14 immune chimeric mice or naïve P14 transgenic 
mice were washed twice in PBS. Cells were resuspended in PBS at a 
concentration of 2 x 107 cells/ml. Equal volumes of cell suspension and 10 µM 
CFSE in PBS were combined, vortexed, and incubated for 10 minutes at room 
temperature (final CFSE concentration of 5µM). After 7 minutes, 1/10th volume of 
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fetal bovine serum (FBS) was added. After 10 minutes, CFSE was diluted with 
RPMI 1640 containing 10% FBS and washed twice.  Following incubation, cells 
were resuspended in RPMI for injection, and 3 - 5 x 106 cells were injected i.v. or 
i.t. into C57Bl/6 recipient mice. 
Pertussis Toxin Treatment 
Purified splenocytes from P14 immune chimeric mice were incubated in 25 ng/ml 
Pertussis Toxin (Sigma-Aldrich) in RPMI containing 10% FBS and 10 mM 
HEPES at a concentration of 30 x 106 cells/ml for 1h at 37°C as described (119, 
254). Following incubation, cells were washed to remove excess pertussis toxin 
and 5 x 106 cells were injected i.t. into C57Bl/6 recipient mice. 
In vitro stimulation for proliferation induction 
The medium used for cell cultures was RPMI 1640 supplemented with 10% FBS, 
2mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml 
Amphotericin B, and 50 µM 2-mercaptoethanol (RP-10 media). Purified 
splenocytes from naïve congenic mice were incubated in RP-10 containing 0.1 
µg/ml gp33-41 peptide in 15mL conical tube or flat-bottom 96 well plates for 30 
minutes at 37°C (5% CO2). Memory P14 T splenocytes were incubated in flat-
bottom 96-well plates in RP-10 media co-cultured with media or peptide-treated 
congenic splenocytes for 16-96 hours at 37°C (5% CO2). 
In vitro re-stimulation and staining for intracellular cytokine production 
The medium used for in vitro re-stimulation cell cultures was RPMI 1640 
supplemented with 10% FBS, 2mM L-glutamine, 100 U/ml penicillin, 100 mg/ml 
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streptomycin, 1x non-essential amino acids (MEM NEAA 100x, Gibco, Life 
Technologies), 1 mM sodium pyruvate (Cellgro, Mediatech), 50 µM 2-
mercaptoethanol, and 10 mM HEPES (Aliclone media). Donor P14 T cells 
recovered from airway or spleen were incubated in 15mL conical tube or flat-
bottom 96-well plates in Aliclone media with or without 0.1µg/ml gp33-41 peptide 
for 4 hours at 37°C.  
Parabiosis 
Congenically marked KLF2GFP P14 T cells were transferred into C57Bl/6 mice. 
One day later, the mice were infected with LCMV. 30-65 days later, mice 
underwent parabiotic surgery as per the schematic in Figure 4-6a, and as 
described (126). Briefly, mice were anesthetized with ketamine, flank hair 
removed using nair, and the skin cleaned using betadine. A lateral incision was 
made on each mouse from knee to elbow. Mice were joined using a continuous 
sub-cuticular suture on both the dorsal and ventral sides, with mattress and 
cruciate sutures joining the skin layer. Mattress sutures just under the armpit and 
knee were made to secure the parabiosed mice. 7-9 days after surgery, mice 
were bled via the retro-orbital route to ensure equilibrium between circulating 
cells. At 28 days after surgery, intravascular staining was performed and tissues 
were harvested from both mice. The number of non-vascular-associated P14 
memory T cells was calculated in both “donor” and “parabiont” with respect to the 
original host for each cell type. A minimum threshold of 25 events was applied for 
calculation of P14 T cell KLF2GFP and CD69 MFI. 
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Statistical analysis 
Data were analyzed using Prism software 5 (GraphPad). For standard data sets, 
an unpaired two-tailed Student’s t-test was used. The number of biological 
repeats is indicated in the figure legends. Asterisks indicate obtained P values: *, 
p<0.05; **, p<0.01; ***, p<0.005, ****, p<0.001 
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Discussion 
The work presented in this thesis validates a method of intravascular 
staining that distinguishes blood-borne from tissue-localized leukocytes and 
expands the utility of this technique to novel situations examining many leukocyte 
lineages and model systems of disease. One of the major recurrent observations 
within these studies is that perfusion of the heart and pulmonary vasculature with 
a saline buffer solution is insufficient to completely remove leukocytes from the 
vascular circulation. Even more surprising was the discovery that this method of 
flushing the vasculature actually removes tissue-localized cells, which may be of 
interest to investigators. Therefore, for thorough and accurate analysis of 
leukocyte contributions to disease processes in tissues, incorporation of 
intravascular staining in lieu of perfusion has notable advantages. Investigators 
can confidently exclude vascular cells from analysis of tissue-localized responses 
while comparing tissue- and blood-borne cells for a more complete and dynamic 
understanding of local biological processes. 
The initial goal of this work was to examine the primary and anamnestic 
CD8 T cell responses to respiratory pathogens. However, our initial studies 
revealed an unexpected advantage of intravascular staining. Our data suggested 
that many outstanding conflicts within the literature regarding leukocyte 
differentiation state, migration pattern, and functional capacity within the lung 
could be explained by distinguishing between blood and tissue compartments. 
For instance, several studies have suggested that naïve lymphocytes enter the 
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lung tissue as a method of patrolling non-lymphoid tissues and maintaining 
peripheral tolerance (107-109, 111). However, the studies with intravascular 
staining discussed in Chapter 3 suggest that naïve lymphocytes in the 
uninflamed lung are confined to the vasculature. Further, studies involving 
blockade of chemokine receptor signaling via pertussis toxin treatment suggest 
that migration to the lung parenchyma is distinct from the traditional paradigm of 
lymphocyte migration (108-110). The studies in Chapters 2 and 3 that 
incorporate intravascular staining refute these interpretations by confirming that 
blockade of chemokine receptor signaling results in obstructed tissue entry by 
lymphocytes. Thus, intravascular staining clarifies seemingly paradoxical findings 
with respect to lymphocyte differentiation and migration in the lung tissue. 
In light of this new understanding of tissue compartments, previously 
published data can be revisited and considered in a new context. For example, 
monocytes have been shown to undergo differentiation into either macrophages 
or DCs upon entry of inflamed tissue (247). However, Jakubzick and colleagues 
recently proposed that monocytes circulate through non-lymphoid tissues, such 
as the lung, and return to lymph nodes in an undifferentiated state (148). Using 
various flow cytometric and transcriptome analyses, the investigators argue that 
monocytes isolated from the peripheral blood, lymph node and lung express 
comparable levels of the characteristic molecules of classical, undifferentiated 
monocytes. While the data are consistent with the investigators’ hypothesis, an 
alternative explanation could also account for these results: monocytes in the 
lung vasculature that are refractory to perfusion have not been excluded from the 
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analysis. Incorporation of intravascular staining would allow for the exclusion of 
confounding blood-borne monocytes and warrant a more in depth analysis of true 
tissue-localized cells of the monocyte lineage. Thus, a new appreciation for 
leukocyte location within tissue compartments invites a re-visitation of previous 
work, especially of findings within vascular organs such as the lung, liver and 
kidneys. Moreover, the addition of a straightforward method for the identification 
of vascular leukocytes has the ability to enhance our understanding of dynamic 
processes within lymphoid and non-lymphoid tissues.  
The data presented in Chapter 3 also indicate that intravascular staining 
has the potential to dramatically influence our understanding of immune 
responses to Mycobacterium tuberculosis (Mtb). The data demonstrate that T 
cells within the lung tissue of Mtb-infected mice have increased expression of the 
inhibitory ligand programmed death-1 (PD-1) over cells within the vascular 
circulation. While expression of this marker is indicative of recent antigen 
exposure and signaling through the T cell receptor (308), prolonged expression 
has also been correlated with a functionally impaired differentiation program in 
models of chronic infection (309). It may be that T cells primed during an Mtb 
infection enter the lung tissue and become less functional over the extended time 
frame required for containing the chronic infection. Perhaps while attempting to 
contribute to control of the pathogen, T cell function is dampened as a 
mechanism for controlling T cell-mediated pathology. Experiments examining 
IFN-γ secretion and perforin and granzyme expression within lymphocytes in the 
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lung tissue will add to our understanding of T cell mechanisms of immune control 
of Mtb infection.   
Intravascular staining has also added to our understanding of myeloid 
immune responses to Mtb. The analysis of multiple subsets of myeloid cells in 
Chapter 3 suggests that inflammatory monocyte derived dendritic cells (moDCs) 
are the major myeloid cell type within the lung tissue during Mtb infection. While 
this subset of myeloid cells is known to produce the pro-inflammatory cytokines 
IL-1α, IL-1β, and TNF-α as well as inducible nitric oxide species (177), moDCs 
also produce the anti-inflammatory cytokine IL-10. Thus, additional studies are 
needed to fully elucidate the contribution of these cells to the response against 
Mtb. 
Intravascular staining has also allowed for a much more thorough analysis 
of the phenomenon of resident memory within tissues. For some time, memory T 
cells were characterized as either central memory, which recirculate between 
blood, lymph, and secondary lymphoid organs, or effector memory, which were 
all thought to recirculate between blood, lymph, and non-lymphoid tissues. 
Recently, a non-recirculating subset of memory T cells that resides permanently 
in non-lymphoid tissues has been described in several organs, including the skin, 
intestine, kidney, brain, lung, and female reproductive tract (251). This subset is 
most often referred to as T resident memory (TRM). TRM cells have been shown to 
protect against viral infections in the skin (122, 228) and lung (124), and 
precipitate local inflammatory cascades that recruit circulating T cells to sites of 
infection (123). Intravascular staining provides an added advantage to the study 
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of TRM: circulating cells contained within the vasculature can be excluded from 
analysis, allowing for in depth analysis of true tissue lymphocytes.  
A current controversy within the field of TRM revolves around the way in 
which investigators identify non-recirculating cells. Studies using tissue grafts 
and parabiotic murine models identify TRM by assessing the migratory capacity of 
memory T cells. However, these methods are complicated, laborious, and time 
consuming; thus, a major goal within the field has been to identify universal 
phenotypic markers of residency. Since intravascular staining in combination with 
parabiosis allows for the identification of true TRM, this technique has the potential 
to greatly refine the phenotypic markers used in the field as surrogate indicators 
of residency.  
It has been noted that TRM cells often express the C-type lectin CD69 as 
well as the αEβ7 integrin heterodimer (which is most often identified by staining 
cells with antibodies specific for αE, otherwise known as CD103) (251). CD69 
may be associated with retention of TRM because expression antagonizes 
expression of the cell surface molecule sphingosine-1 phosphate receptor 1 
(S1PR1), a protein that promotes egress of lymphocytes into the circulation. αEβ7 
may also contribute directly to the local maintenance of TRM by anchoring T 
lymphocytes to epithelial cells through interactions with E-cadherin (160). 
However, many critical questions remain unanswered: What induces CD69 and 
CD103 expression among T cells in different tissue compartments? What is the 
longevity of resident tissue memory within different locations? How are TRM 
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established within a particular location? And under what conditions do TRM 
contribute to protection?   
 Data from the studies in this thesis and previously published work (124, 
311) demonstrates that TRM within the lung do not universally express CD103. 
More often, TRM within the lung express only CD69, which is a starkly different 
phenotype than TRM isolated from the small intestine epithelium, skin epidermis 
and salivary gland (119, 121, 122, 155). One possible explanation for the 
difference between tissues is in the regulation of CD103 itself. Many studies 
implicate a role for TGF-β in driving CD103 expression. TGF-β is constitutively 
expressed in the small intestinal mucosa, where CD103 is maintained on virtually 
all memory CD8 T cells within the epithelium. And interfering with either TGF-β 
signaling or CD103 expression results in a gradual loss of intestinal intraepithelial 
memory CD8 T cells (155, 158, 159). In contrast, CD103 is expressed by only a 
minority of CD8 T cells in the lung, and many of these cells are lost over time. 
Perhaps TGF-β is also the driver of CD103 expression in the respiratory tract, but 
available TGF-β is maximal only for transient periods after infection. Indeed, loss 
of CD103+ TRM parallels the gradual loss of prolonged antigen-presentation and 
the loss of PD-1 expression (which may reflect recent T cell receptor 
engagement) that occurs within a few months after infection (169, 311, 319, 320). 
This issue merits further investigation, and other factors may regulate TRM 
maintenance within the respiratory mucosa. 
Numerous studies have reported the waning of memory T cell numbers 
within the lung tissue over extended periods of time (168, 169) (Figure 5-1). Thus 
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far, we have no definitive teleological explanation of why local memory in the 
lung wanes. Why would the host not be better served by maintaining protective 
immunity at this site indefinitely? Perhaps there is a cost to such a strategy. 
Indeed, unlike the gut or skin, the lung is a particularly inflammation intolerant 
organ given the delicate architecture necessary for efficient respiration. Once 
local infection has truly been cleared and the innate antiviral state wanes, 
exuberant re-activation of local memory T cells, however helpful for eliminating 
infected host cells, may also be harmful by promoting excessive inflammation 
and pathology. If that is the case, then it is imperative to understand the possible 
pathological consequences of retaining inducible bronchus associated lymphoid 
tissue (iBALT) and TRM in the lung indefinitely. This will, in turn, allow us to 
identify strategies that strike a balance necessary for optimizing host fitness in 
the face of re-infection of the respiratory mucosa: maintaining critical contributors 
to protection without compromising host lung function.  
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Figure 5-1: TRM in the lung is short-lived. Top panel: Effector CD8 T cells enter 
the lung epithelium during the course of viral infection. Middle panel: Early after 
the infection is cleared, effector T cells in the lung epithelium differentiate into a 
specialized population of resident memory CD8 T cells (TRM) that remain in the 
tissue without recirculating. The lung epithelium is not under routine surveillance 
by recirculating (TEM and TCM) memory CD8 T cell subsets. Bottom panel: Unlike 
longer lived memory CD8 T cell subsets, TRM CD8 T cells gradually wane within 
the lung epithelium. 
 
Since direct contact between antigen-specific T cells and the virally-
infected epithelial cells is likely required for their function, the ratio of antigen-
specific cytotoxic cells to target cells becomes an important consideration. How 
many antigen-specific TRM are needed in the lung epithelium for considerable 
protection? Under physiological conditions that experience exposure to a wide 
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variety of pathogens (when a plethora of antigen-specificities are needed), how 
does the frequency of TRM affect lung function? Questions regarding the 
threshold of TRM cells required to optimally enhance local protection remain to be 
addressed (Figure 5-2).  
 
Figure 5-2: The loss of short-lived TRM in the lung correlates with the 
erosion of heterosubtypic immunity against influenza virus. One month after 
primary infection, when TRM in the lung epithelium are abundant, the host exhibits 
rapid control against a heterosubtypic influenza re-challenge. Seven months after 
priming, the number of TRM in the lung airways is greatly reduced, which 
correlates with a pronounced reduction in heterosubtypic protection at this time 
point. This suggests that the maintenance of TRM is critical for optimal 
interception of influenza virus at the primary site of secondary infection. 
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Perhaps one of the most interesting questions raised by recent work 
revolves around the mechanism by which TRM in the lung tissue provide 
protection. It has been shown that memory CD4 T cells in the lung induce innate 
responses upon re-activation, which helps control influenza infection (237). 
Control of influenza A virus infections also depend on Fas and perforin-
dependent cytotoxic processes (321), but T cells in the lung airways may have 
reduced cytolytic function (170, 322). It has been speculated that this reduced 
cytotoxic functionality may be a mechanism for reducing excessive pathology in a 
vital, yet delicate, organ. Perhaps a compromise between maintaining local cell-
mediated protection against pathogens and the need for preserving lung function 
may be related to the gradual waning of TRM numbers in the lung.  
Although antigen-specific TRM in the lung play a critical role in protection in 
cross-reactive infections by direct cytotoxic activity and rapid recruitment of 
“reinforcements”, TRM may also play a significant role in protection by eliciting 
bystander activation. Memory T cells can adopt cytotoxic functionality in 
response to low-level TCR-stimulation as well as TCR-independent stimulation 
by alternative activating receptor ligation, inflammatory cytokines, and toll-like 
receptor (TLR) ligands (162, 323-328). One intriguing possibility is that antigen 
recognition and cytokine secretion by TRM could initiate local bystander activation 
of antigen-nonspecific cells. Bystander-activated cells, which have been shown 
to kill target cells through innate-like mechanisms, could temporarily control 
pathogen replication until additional antigen-specific cells are recruited to the 
tissue. Alternatively, TLR signaling within TRM may also lead to antigen-
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nonspecific T cell activation. Teleologically, bystander activation of TRM may be 
one mechanism by which the immune system balances protection and 
homeostatic function within the delicate architecture of the lung: a minimal TRM 
presence is maintained in the lung tissue to contain pathogens at the portal of 
entry while allowing for optimal gas exchange at alveolar surfaces. Further 
investigation is necessary to elucidate whether this is a possible additional role of 
TRM in the lung. 
Many exciting questions with respect to the establishment, regulation of 
longevity and the protective role of memory T cells in the lung remain to be 
addressed. Local TRM cells promote rapid viral control at the point of viral 
exposure. Although the gradual disappearance of this protective population 
diminishes their potential for long-term protection against future infections, 
additional work may address whether the longevity of this memory population 
can be enhanced. Additionally, as TRM are critical players in rapid pathogen 
clearance against local respiratory challenges, vaccines may be designed that 
optimize their generation. An improved understanding of the contribution of TRM 
to protection during viral challenges has the potential to advance our application 
of this new knowledge to the fight against respiratory infections. As indicated by 
the work in Chapter 4, intravascular staining has the potential to greatly 
contribute to our understanding of resident immune cells within tissues. 
In addition to a broader understanding of immune responses against 
infection, intravascular staining also reveals new insights about immune 
responses within solid tumors. The data in Chapter 3 demonstrate that a large 
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proportion of T cells are protected from intravascular staining, suggesting they 
are contained within the tumor. As in other systems of chronic antigen exposure, 
PD-1 expression is elevated on these T cells, further supporting the hypothesis 
that these cells are truly within the tumor. Interestingly, more than half of the CD8 
T cells protected from intravascular staining express CD69. Without knowing the 
antigen specificity of these T cells, it is difficult to discern if this elevated 
expression is due to recent antigen exposure, similar to PD-1 expression, or if 
this is indicative of TRM within the tumor. 
It is important to note that intravascular staining is not without limitations. 
The studies presented in this thesis are restricted to murine models of disease. 
While the methodology may be adaptable for many small animal systems, the 
necessary modifications have not been examined or addressed in this work. 
Further, systems involving situations of vascular leakage, such as inflammatory 
states or angiogenic tumor models, may compromise the integrity of intravascular 
staining. Vascular permeability assays, such as histological analysis or Evans 
Blue Dye staining, must therefore be performed prior to the incorporation of 
intravascular staining as validating controls. 
In conclusion, investigations of immune responses to viral and bacterial 
infections within most lymphoid and non-lymphoid tissues, as well as models of 
solid tumors, allergy and autoimmunity, and graft-versus-host-disease in small 
animal models may all benefit greatly from the application of intravascular 
staining. While the studies described here are limited to use of intravascular 
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staining in murine models of disease, this technique may be refined so as to be 
applicable in other setting and species. 
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